

Wetenschappelijk overzicht IKNL 2021

Wetenschappelijk overzicht IKNL 2021

Auteur
A.M. Kuijpers-Ruurs

Inhoudsopgave

1	Algemeen	5
	1.1 Publicaties met impactfactor	5
	1.2 Overige publicaties	10
	1.3 Proefschriften en promoties	10
2	Borstkanker	11
	2.1 Publicaties met impactfactor	11
	2.2 Overige publicaties	14
3	Bot-en wekedelentumoren	15
	3.1 Publicaties met impactfactor	15
	3.2 Overige publicaties	15
4	Darmkanker	16
	4.1 Publicaties met impactfactor	16
5	Gynaecologische tumoren	22
	5.1 Publicaties met impactfactor	22
	5.2 Overige publicaties	24
6	Hemato-oncologie	25
	6.1 Publicaties met impactfactor	25
	6.2 Overige publicaties	26
7	Hoofdhalskanker	27
	7.1 Publicaties met impactfactor	27
	7.2 Overige publicaties	28
8	Huidkanker	29
	8.1 Publicaties met impactfactor	29
9	Longkanker	31
	9.1 Publicaties met impactfactor	31
	9.2 Overige publicaties	33
10	Neuro-oncologie	34
	10.1 Publicaties met impactfactor	34
	10.2 Overige publicaties	34
11	Upper GI & HPB	35
	11.1 Publicaties met impactfactor	35
	11.2 Proefschriften en promoties	38
12	Urogenitale kanker	39
	12.1 Publicaties met impactfactor	39
	12.2 Overige publicaties	41
B1	Impactfactoren tijdschriften	42

1 Algemeen

1.1 Publicaties met impactfactor

Agyemang C, **Richters A**, Jolani S, Hendriks S, Zalpuri S, Yu E, Pijls B, Prins M, Stronks K, Zeegers MP. Ethnic minority status as social determinant for COVID-19 infection, hospitalisation, severity, ICU admission and deaths in the early phase of the pandemic: a meta-analysis. *BMJ Glob Health*. 2021 Nov;6(11):e007433. doi: 10.1136/bmjgh-2021-007433. Impactfactor: 5,558

Boddaert MS, Stoppelenburg A, Hasselaar J, van der Linden YM, Vissers KC, **Raijmakers NJ, Brom L**. Specialist palliative care teams and characteristics related to referral rate: a national cross-sectional survey among hospitals in the Netherlands. *BMC Palliat Care*. 2021 Nov 11;20(1):175. doi: 10.1186/s12904-021-00875-3. Impactfactor: 3,234

Chan RJ, Nekhlyudov L, **Duijts SF**, Hudson SV, Jones JM, Keogh J, Love B, Lustberg MB, Mehnert-Theuerkauf A, Nathan P, Ness KK, Sheppard VB, Smith K, Tevaarwerk A, Yu X, Feuerstein M. *Future research in cancer survivorship*. *J Cancer Surviv*. 2021 Aug 30. doi: 10.1007/s11764-021-01102-x. Online ahead of print. Impactfactor: 4,442

Chan RJ, Crichton M, Crawford-Williams F, Agbejule OA, Yu K, Hart NH, de Abreu Alves F, Ashbury FD, Eng L, Fitch M, Jain H, Jefford M, Klemanski D, Koczwara B, Loh K, Prasad M, Rugo H, Soto-Perez-de-Celis E, **van den Hurk CJ**, Chan A; Multinational Association of Supportive Care in Cancer (MASCC) Survivorship Study Group. *The efficacy, challenges, and facilitators of telemedicine in post-treatment cancer survivorship care: an overview of systematic reviews*. *Ann Oncol*. 2021 Sep 9:S0923-7534(21)04464-1. doi: 10.1016/j.annonc.2021.09.001. Online ahead of print. Impactfactor: 32,976

Cheung YT, Chan A, Charalambous A, Darling HS, Eng L, Grech L, **van den Hurk CJ**, Kirk D, Mitchell SA, Poprawski D, Rammant E, Ramsey I, Fitch MI, Chan RJ; Multinational Association for Supportive Care in Cancer Survivorship Study Group. YT Cheung is the first author, MI Fitch and RJ Chan are co-corresponding authors. All other authors will be listed in alphabetical order by their last names. *The use of patient-reported outcomes in routine cancer care: preliminary insights from a multinational scoping survey of oncology practitioners*. *Support Care Cancer*. 2021 Sep 15:1-13. doi: 10.1007/s00520-021-06545-7. Online ahead of print. Impactfactor: 3,603

Damen A, Raijmakers NJ, van Roij J, Visser A, Beuken-Everdingen MV, Kuip E, van Laarhoven HW, van Leeuwen-Snoeks L, van der Padt-Pruijsten A, Smilde TJ, Leget C, Fitchett G. *Spiritual well-being and associated factors in Dutch patients with advanced cancer*. *J Pain Symptom Manage*. 2021 Oct 15:S0885-3924(21)00571-6. doi: 10.1016/j.jpainsymman.2021.10.004. Online ahead of print. Impactfactor: 3,612

Damen A, Visser A, van Laarhoven HW, Leget C, **Raijmakers NJ, van Roij J**, Fitchett G. *Validation of the FACIT-Sp-12 in a Dutch cohort of patients with advanced cancer*. *Psychooncology*. 2021 Jul 13. doi: 10.1002/pon.5765. Online ahead of print. Impactfactor: 3,894

de Heus E, Engelen V, Dingemans I, Richel C, Schrieks M, **van der Zwan JM**, Besselink MG, van Berge Henegouwen MI, van Herpen CM, **Duijts SF**. *Differences in health care experiences between rare cancer and common cancer patients: results from a national cross-sectional survey*. *Orphanet J Rare Dis*. 2021 Jun 1;16(1):249. doi: 10.1186/s13023-021-01886-2. Impactfactor: 4,123

de Heus E, van der Zwan JM, Husson O, Frissen AR, van Herpen CM, Merckx MA, Duijts SF. Unmet supportive care needs of patients with rare cancer: a systematic review. *Eur J Cancer Care (Engl)*. 2021 Aug 18:e13502. doi: 10.1111/ecc.13502. Online ahead of print.
Impactfactor: 2,52

de Rooij BH, Oerlemans S, van Deun K, Mols F, de Ligt KM, Husson O, Ezendam NP, Hoedjes M, van de Poll-Franse LV, Schoormans D. Symptom clusters in 1330 survivors of 7 cancer types from the PROFILES registry: a network analysis. *Cancer*. 2021 Aug 13. doi: 10.1002/cncr.33852. Online ahead of print.
Impactfactor: 6,86

Duijts SF, Spelten ER. Cancer survivorship issues: dissemination and translation of evidence-based knowledge. *Cancers (Basel)*. 2021 Nov 18;13(22):5794. doi: 10.3390/cancers13225794.
Impactfactor: 6,639

Duijts SF, van der Zwan JM. Rare cancers and cancer of unknown primary: here's what you should know! *Eur J Cancer Care (Engl)*. 2021 Nov;30(6):e13508. doi: 10.1111/ecc.13508.
Impactfactor: 2,52

Dijxhoorn AQ, Brom L, van der Linden YM, Leget C, Raijmakers NJ. Healthcare professionals' work-related stress in palliative care: a cross-sectional survey. *J Pain Symptom Manage*. 2021 Apr 14:S0885-3924(21)00284-0. doi: 10.1016/j.jpainsymman.2021.04.004. Online ahead of print.
Impactfactor: 3,612

Fox L, Beyer K, Rammant E, Morcom E, Van Hemelrijck M, Sullivan R, Vanderpuye V, Lombe D, Tsunoda AT, Kutluk T, Bhoo-Pathy N, Pramesh SC, Yusuf A, Booth CM, Shamieh O, **Siesling S, Mukherji D.** Impact of the COVID-19 pandemic on cancer researchers in 2020: a qualitative study of events to inform mitigation strategies. *Front Public Health*. 2021 Nov 24;9:741223. doi: 10.3389/fpubh.2021.741223. eCollection 2021.
Impactfactor: 3,709

Grewcock AR, Hermans KE, Weijenberg MP, van den Brandt PA, **Loef C, Jansen RL, Schouten LJ.** Family history of cancer in first degree relatives and risk of cancer of unknown primary. *Eur J Cancer Care (Engl)*. 2021 Jul 5. doi: 10.1111/ecc.13485. Online ahead of print.
Impactfactor: 2,52

Ham L, Fransen HP, van den Borne B, Hendriks MP, van Laarhoven HW, van der Padt-Pruijsten A, Raijmakers NJ, van Roij J, Sommeijer DW, Vriens BE, van Zuylen L, van de Poll-Franse LV. Bereaved relatives' quality of life before and during the COVID-19 pandemic: results of the prospective, multicenter, observational eQuiPe study. *Palliat Med*. 2021 Jul 20:2692163211034120. doi: 10.1177/02692163211034120. Online ahead of print.
Impactfactor: 4,762

Hermans KE, van den Brandt PA, **Loef C, Jansen RL, Schouten LJ.** Meat consumption and cancer of unknown primary (CUP) risk: results from The Netherlands cohort study on diet and cancer. *Eur J Nutr*. 2021 Jun 21. doi: 10.1007/s00394-021-02600-5. Online ahead of print.
Impactfactor: 5,619

Hugen N, Kanne H, Simmer F, van de Water C, Voorham QJ, **Ho VK, Lemmens VE, Simons M, Nagtegaal ID.** Umbilical metastases: real-world data shows abysmal outcome. *Int J Cancer*. 2021 May 14. doi: 10.1002/ijc.33684. Online ahead of print.
Impactfactor: 7,396

Hollestein LM, Lo SN, Leonardi-Bee J, Rosset S, Shomron N, Couturier DL, Gran S. MULTIPLE ways to correct for MULTIPLE comparisons in MULTIPLE types of studies. *Br J Dermatol*. 2021 Dec;185(6):1081-1083. doi: 10.1111/bjd.20600.
Impactfactor: 9,302

Husson O, Ligtenberg MJ, **van de Poll-Franse LV**, Prins JB, van den Bent MJ, **van Eenbergen MC**, Fles R, Manten-Horst E, Gietema JA, van der Graaf WT. Comprehensive assessment of incidence, risk factors, and mechanisms of impaired medical and psychosocial health outcomes among adolescents and young adults with cancer: protocol of the prospective observational COMPRAYA cohort study. *Cancers (Basel)*. 2021 May 13;13(10):2348. doi: 10.3390/cancers13102348.PMID: 34068026. Impactfactor: 6,639

Jabbarian LJ, Rietjens JA, **Mols F**, Oude Groeniger J, van der Heide A, Korlage IJ. Untangling the relationship between negative illness perceptions and worse quality of life in patients with advanced cancer: a study from the population-based PROFILES registry. *Support Care Cancer*. 2021 Apr 23. doi: 10.1007/s00520-021-06179-9. Online ahead of print. Impactfactor: 3,603

Kehrloesser S, Oberst S, **Westerhuis W**, Wendler A, Wind A, **Blaauwgeers H**, Burrión JB, Nagy P, Saeter G, Gustafsson E, De Paoli P, Lovey J, Lombardo C, Philip T, de Valeriola D, Docter M, Boomsma F, Saghatchian M, Svoboda M, Philip I, Monetti F, **Hummel H**, McVie G, Otter R, van Harten W. Analysing the attributes of Comprehensive Cancer Centres and Cancer Centres across Europe to identify key hallmarks. *Mol Oncol*. 2021 Mar 18. doi: 10.1002/1878-0261.12950. Impactfactor: 6,603

Klaver KM, Schagen SB, Kieffer JM, van der Beek AJ, **Duijts SF**. Trajectories of cognitive symptoms in sick-listed cancer survivors. *Cancers (Basel)*. 2021 May 18;13(10):2444. doi: 10.3390/cancers13102444. Impactfactor: 6,639

Kroon LL, van Roij J, Korlage IJ, Reyners AK, van den Beuken-van Everdingen MH, den Boer MO, Creemers GJ, de Graeff A, Hendiks MP, Hunting JC, de Jong WK, Kuip EJ, van Laarhoven HW, van Leeuwen L, van Lindert AS, Mandigers CM, Nieboer P, van der Padt-Pruijsten A, Smilde TJ, Sommeijer DW, Thijs MF, Tiemessen MA, Vos AH, Vreugdenhil A, Werner PT, van Zuylen L, **van de Poll-Franse LV, Raijmakers NJ**; eQuiPe study group. Perceptions of involvement in advance care planning and emotional functioning in patients with advanced cancer. *J Cancer Surviv*. 2021 Apr 10. doi: 10.1007/s11764-021-01020-y. Online ahead of print. Impactfactor: 4,442

Kuiper JG, van Herk-Sukel MP, **Lemmens VE**, Kuipers EJ, Herings RM. A population-based linked cohort of cancer and primary care data: a new source to study the management of cancer in primary care. *Eur J Cancer Care (Engl)*. 2021 Oct 17:e13529. doi: 10.1111/ecc.13529. Impactfactor: 2,52

Lidington E, Darlington AS, **Vlooswijk C**, Beardsworth S, McCaffrey S, Tang S, Stallard K, Younger E, Edwards P, Ali AI, Nandhabalan M, Din A, Starling N, Larkin J, Stanway S, Nobbenhuis M, Banerjee S, Szucs Z, Gonzalez M, Sirohi B, Husson O, van der Graaf WTA. Beyond teenage and young adult cancer care: care experiences of patients aged 25-39 years old in the UK National Health Service. *Clin Oncol (R Coll Radiol)*. 2021 Mar 12:S0936-6555(21)00053-4. doi: 10.1016/j.clon.2021.02.010. Impactfactor: 4,126

Lidington E, **Vlooswijk C**, Stallard K, Travis E, Younger E, Edwards P, Nandhabalan M, Hunter N, Sarpal N, Flett D, Din A, Starling N, Larkin J, Stanway S, Nobbenhuis M, Banerjee S, Szucs Z, Darlington AS, Gonzalez M, Sirohi B, van der Graaf WT, Husson O. 'This is not part of my life plan': a qualitative study on the psychosocial experiences and practical challenges in young adults with cancer age 25 to 39 years at diagnosis. *Eur J Cancer Care (Engl)*. 2021 May 3:e13458. doi: 10.1111/ecc.13458. Online ahead of print. Impactfactor: 2,52

Lize N, IJmker-Hemink V, van Lieshout R, Wijnholds-Roeters Y, van den Berg M, Soud MY, **Beijer S, Raijmakers NJ**. Experiences of patients with cancer with information and support for psychosocial consequences of reduced ability to eat: a qualitative interview study. *Support Care Cancer*. 2021 Apr 21. doi: 10.1007/s00520-021-06217-6. Online ahead of print. Impactfactor: 3,603

Loef C, Merks MA. Cancer of unknown primary origin; know the enemy. *Eur J Cancer Care (Engl)*. 2021 May 11:e13460. doi: 10.1111/ecc.13460. Online ahead of print. Impactfactor: 2,52

Meijer L, Verhoeven RH, de Hingh IH, van de Wouw AJ, van Laarhoven HW, **Lemmens VE, Loef C**. Extensive diagnostic work-up for patients with carcinoma of unknown primary. *Clin Exp Metastasis*. 2021 Jan 30. doi: 10.1007/s10585-021-10073-3. Online ahead of print. Impactfactor: 5,15

Neamtiu L, Martos C, Giusti F, Negrao Carvalho R, Randi G, Dimitrova N, Flego M, Dyba T, Bettio M, Gavin A, **Visser O**; ENCR Steering Committee. Impact of the first wave of the COVID-19 pandemic on cancer registration and cancer care: a European survey. *Eur J Public Health*. 2021 Dec 22:ckab214. doi: 10.1093/eurpub/ckab214. Online ahead of print. Impactfactor: 3,367

Oerlemans S, Schagen SB, **van den Hurk CJ**, Husson O, Schoormans D, **van de Poll-Franse LV**. Self-perceived cognitive functioning and quality of life among cancer survivors: results from the PROFILES registry. *J Cancer Surviv*. 2021 Mar 17. doi: 10.1007/s11764-021-01023-9. Impactfactor: 4,442

Oertelt-Prigione S, **de Rooij BH, Mols F, Oerlemans S**, Husson O, Schoormans D, Haanen JB, **van de Poll-Franse LV**. Sex-differences in symptoms and functioning in >5000 cancer survivors: Results from the PROFILES registry. *Eur J Cancer*. 2021 Aug 16;156:24-34. doi: 10.1016/j.ejca.2021.07.019. Online ahead of print. Impactfactor: 9,162

Oosting SF, van der Veldt AA, GeurtsvanKessel CH, Fehrmann RS, van Binnendijk RS, Dingemans AC, Smit EF, Hiltermann TJ, den Hartog G, Jalving M, **Westphal TT**, Bhattacharya A, van der Heiden M, Rimmelzwaan GF, Kvistborg P, Blank CU, Koopmans MP, Huckriede AL, van Els CA, Rots NY, van Baarle D, Haanen JB, de Vries EG. mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trial. *Lancet Oncol*. 2021 Nov 9:S1470-2045(21)00574-X. doi: 10.1016/S1470-2045(21)00574-X. Online ahead of print. Impactfactor: 41,316

Pijls BG, Jolani S, Atherley A, Derckx RT, Dijkstra JI, Franssen GH, Hendriks S, **Richters A**, Venemans-Jellema A, Zalpuri S, Zeegers MP. Demographic risk factors for COVID-19 infection, severity, ICU admission and death: a meta-analysis of 59 studies. *BMJ Open*. 2021 Jan 11;11(1):e044640. doi: 10.1136/bmjopen-2020-044640. Impactfactor: 2,692

Rumgay H, Shield K, Charvat H, Ferrari P, Sormpaisarn B, Obot I, Islami F, **Lemmens VE**, Rehm J, Soerjomataram I. Global burden of cancer in 2020 attributable to alcohol consumption: a population-based study. *Lancet Oncol*. 2021 Jul 13;22(8):1071-80. doi: 10.1016/S1470-2045(21)00279-5. Online ahead of print. Impactfactor: 41,316

Schulpen M, **Visser O**, Reedijk AM, Kremer LC, Zwaan CM, Eggermont AM, Coebergh JW, Pieters R, **Karim-Kos HE**. Significant improvement in survival of advanced stage childhood and young adolescent cancer in the Netherlands since the 1990s. *Eur J Cancer*. 2021 Sep 4;157:81-93. doi: 10.1016/j.ejca.2021.08.001. Online ahead of print. Impactfactor: 9,162

Smith TG, Beckwitt AE, **van de Poll-Franse LV**, Bontemps-Jones JE, James TA, McCabe RM, Francescatti AB, Aaronson NK. Oncology team perspectives on distress screening: a multisite study of a well-established use of patient-reported outcomes for clinical assessment. *Support Care Cancer*. 2021 Sep 1. doi: 10.1007/s00520-021-06458-5. Online ahead of print. Impactfactor: 3,603

Spelten ER, van Vuuren J, Naess K, Timmis J, Hardman R, **Duijts S**. Making community palliative and end-of-life care sustainable; investigating the adaptability of rural Australian service provision. *Health Soc Care Community*. 2021 Mar 17. doi: 10.1111/hsc.13344. Impactfactor: 2,821

van Beek FE, Wijnhoven LM, Custers JA, Holtmaat K, **de Rooij BH**, **Horevoorts NJ**, Aukema EJ, Verheul S, Eerenstein SE, Strobbe L, Van Oort IM, Vergeer MR, Prins JB, Verdonck-de Leeuw IM, Jansen F. **Adjustment disorder in cancer patients after treatment: prevalence and acceptance of psychological treatment**. *Support Care Cancer*. 2021 Oct 2. doi: 10.1007/s00520-021-06530-0. Impactfactor: 3,603

van de Graaf DL, Trompetter HR, Smeets T, **Mols F**. **Online acceptance and commitment therapy (ACT) interventions for chronic pain: a systematic literature review**. *Internet Interv*. 2021 Oct 1;26:100465. doi: 10.1016/j.invent.2021.100465. eCollection 2021 Dec. Impactfactor: 4,333

van der Hout A, van Uden-Kraan CF, Holtmaat K, Jansen F, Lissenberg-Witte BI, Nieuwenhuijzen GA, Hardillo JA, Baatenburg de Jong RJ, Tiren-Verbeet NL, Sommeijer DW, de Heer K, Schaar CG, Sedee RJ, Bosscha K, van den Brekel MW, Petersen JF, Westerman M, Honings J, Takes RP, Houtenbos I, van den Broek WT, de Bree R, Jansen P, Eerenstein SE, Leemans CR, Zijlstra JM, Cuijpers P, **van de Poll-Franse LV**, Verdonck-de Leeuw IM. **Reasons for not reaching or using web-based self-management applications, and the use and evaluation of Oncokompas among cancer survivors, in the context of a randomised controlled trial**. *Internet Interv*. 2021 Jul 15;25:100429. doi: 10.1016/j.invent.2021.100429. eCollection 2021 Sep. Impactfactor: 4,333

van der Veldt AA, Oosting SF, Dingemans AC, Fehrmann RS, Geurts van Kessel C, Jalving M, Rimmelzwaan GF, Kvistborg P, Blank CU, Smit EF, **Lemmens VE**, Hiltermann TJ, Koopmans MP, Huckriede AL, Rots NY, van Els CA, van Baarle D, Haanen JB, de Vries EG. **COVID-19 vaccination: the VOICE for patients with cancer**. *Nat Med*. 2021 Feb 15. doi: 10.1038/s41591-021-01240-w. Online ahead of print. Impactfactor: 53,44

van Roij J, Kieffer JM, **van de Poll-Franse LV**, Husson O, **Raijmakers NJ**, Gelissen J. **Assessing measurement invariance in the EORTC QLQ-C30**. *Qual Life Res*. 2021 Jul 29. doi: 10.1007/s11136-021-02961-8. Online ahead of print. Impactfactor: 4,147

van Roij J, **Brom L**, Sommeijer D, **van de Poll-Franse LV**, **Raijmakers NJ**; eQuiPe study group. **Self-care, resilience, and caregiver burden in relatives of patients with advanced cancer: results from the eQuiPe study**. *Support Care Cancer*. 2021 Jul 3. doi: 10.1007/s00520-021-06365-9. Online ahead of print. Impactfactor: 3,603

van Roij J, **de Zeeuw B**, **Zijlstra M**, Claessens N, **Raijmakers N**, **de Poll-Franse LV**, **Brom L**. **Shared perspectives of patients with advanced cancer and their informal caregivers on essential aspects of health care: a qualitative study**. *J Palliat Care*. 2021 Feb 5;825859721989524. doi: 10.1177/0825859721989524. Online ahead of print. Impactfactor: 2,25

van Tuijl LA, **Voogd AC**, de Graeff A, Hoogendoorn AW, Ranchor AV, Pan KY, Basten M, Lamers F, Geerlings MI, Abell JG, Awadalla P, Bakker MF, Beekman AT, Bjerkeset O, Boyd A, Cui Y, Galenkamp H, Garsen B, Hellingman S, Huisman M, Huss A, Keats MR, Kok AA, Luik AI, Noisel N, Onland-Moret NC, Payette Y, Penninx BW, Portengen L, Rissanen I, Roest AM, Rosmalen JG, Ruiters R, Schoevers RA, Soave DM, Spaan M, Steptoe A, Stronks K, Sund ER, Sweeney E, Teyhan A, Vaartjes I, van der Willik KD, van Leeuwen FE, van Petersen R, Verschuren WM, Visseren F, Vermeulen R, Dekker J. **Psychosocial factors and cancer incidence (PSY-CA): protocol for individual participant data meta-analyses**. *Brain Behav*. 2021 Sep 2:e2340. doi: 10.1002/brb3.2340. Online ahead of print. Impactfactor: 2,708

Vlooswijk C, Husson O, Krahmer EJ, Bijlsma R, Kaal SE, Sleeman SH, **van de Poll-Franse LV**, van der Graaf WT, Bol N, **van Eenbergen MC**. **Differences in internet use and eHealth needs of adolescent and young adult versus older cancer patients: results from the PROFILES Registry**. *Cancers (Basel)*. 2021 Dec 16;13(24):6308. doi: 10.3390/cancers13246308. Impactfactor: 6,639

Vlooswijk C, Husson O, **Oerlemans S**, **Ezendam NP**, Schoormans D, **de Rooij BH**, **Mols F**. Self-reported causes of cancer among 6881 survivors with 6 tumour types: results from the PROFILES registry. *J Cancer Surviv*. 2021 Mar 1. doi: 10.1007/s11764-021-00989-w. Online ahead of print. Impactfactor: 4,442

Vromans RD, **van Eenbergen MC**, **Geleijnse G**, Pauws S, **van de Poll-Franse LV**, Krahmer EJ. Exploring cancer survivor needs and preferences for communicating personalized cancer statistics from registry data: qualitative multimethod study. *JMIR Cancer*. 2021 Oct 25;7(4):e25659. doi: 10.2196/25659. Impactfactor: 0,53

Wind A, van der Linden C, Hartman E, **Siesling S**, van Harten W. Patient involvement in clinical pathway development, implementation and evaluation: a scoping review of international literature. *Patient Educ Couns*. 2021 Oct 8:S0738-3991(21)00663-7. doi: 10.1016/j.pec.2021.10.007. Impactfactor: 2,940

Wind A, Hartman ED, Van Eekeren RR, Wijn RP, Halámková J, Mattson J, **Siesling S**, van Harten WH. Validating a generic cancer consumer quality index in eight European countries, patient reported experiences and the influence of cultural differences. *BMC Cancer*. 2021 Mar 6;21(1):231. doi: 10.1186/s12885-021-07943-0. Impactfactor: 4,43

Yim J, Shaw J, Viney R, Arora S, **Ezendam NP**, Pearce A. Investigating the association between self-reported comorbid anxiety and depression and health service use in cancer survivors. *Pharmacoeconomics*. 2021 Apr 5. doi: 10.1007/s40273-021-01016-7. Online ahead of print. Impactfactor: 4,981

Zegers AD, Coenen P, Bültmann U, Retèl V, Kieffer JM, van der Beek AJ, **Duijts SF**. Supporting participation in paid work of cancer survivors and their partners in the Netherlands: protocol of the Sustained Employability in cancer Patients and their partnerS (STEPS) multi-centre randomized controlled trial and cohort study. *BMC Public Health*. 2021 Oct 12;21(1):1844. doi: 10.1186/s12889-021-11865-8. Impactfactor: 3,295

1.2 Overige publicaties

Moncada-Torres A, **Martin F**, **Sieswerda M**, van Soest J, **Geleijnse G**. VANTAGE6: an open source privacy preserving federated learning infrastructure for Secure Insight eXchange. *AMIA Annu Symp Proc*. 2021 Jan 25;2020:870-877. eCollection 2020.

Ijmker-Hemink V, **Lize N**, **Beijer S**, **Raijmakers NJ**, Wanten G, van den Berg M. Lessons learned from a randomized controlled trial on a home delivered meal service in advanced cancer patients undergoing chemotherapy: a pilot study. *BMC Nutr*. 2021 Feb 16;7(1):4. doi: 10.1186/s40795-021-00407-5.

1.3 Proefschriften en promoties

Bonhof CS. Chemotherapy-induced peripheral neuropathy: a nerve-wracking condition affecting patients' quality of life. Tilburg: Tilburg University; 29 maart 2021. Promotor: **LV van de Poll-Franse**. Copromotores: **F Mols**, G Vreugdenhil. Overige leden: GJ Creemers, V Engelen, CG Faber, ML van der Lee, **VE Lemmens**, T Smeets.

van den Berg-Verberkt C. Chronic breathlessness in COPD: effects of low-dose oral morphine. Maastricht: Maastricht University; 29 oktober 2021.

van Eenbergen MC. Cancer and the internet: how patients collect, connect and communicate to cope with cancer. Tilburg: Tilburg University; 7 juli 2021. Promotores: **LV van de Poll-Franse**, EJ Krahmer. Copromotor: **F Mols**.

2 Borstkanker

2.1 Publicaties met impactfactor

Ankersmid JW, [van Hoeve JC](#), Strobbe LJ, van Riet YE, van Uden-Kraan CF, [Siesling S](#), Drossaert CH; Santeon VBHC Breast Cancer Group. [Follow-up after breast cancer: Variations, best practices, and opportunities for improvement according to health care professionals](#). *Eur J Cancer Care (Engl)*. 2021 Aug 27:e13505. doi: 10.1111/ecc.13505. Online ahead of print.

Impactfactor: 2,52

Dackus GM, Józwiak K, Sonke GS, van der Wall E, van Diest PJ, [Siesling S](#), Hauptmann M, Linn SC. [Adjuvant aromatase inhibitors or tamoxifen following chemotherapy for perimenopausal breast cancer patients](#). *J Natl Cancer Inst*. 2021 Jun 8:djab091. doi: 10.1093/jnci/djab091. Online ahead of print.

Impactfactor: 13,506

de Boer AZ, Bastiaannet E, Putter H, Marang-van de Mheen PJ, [Siesling S](#), [de Munck L](#), [de Ligt KM](#), Portielje JE, Liefers GJ, de Glas NA. [Prediction of other-cause mortality in older patients with breast cancer using comorbidity](#). *Cancers (Basel)*. 2021 Apr 1;13(7):1627. doi: 10.3390/cancers13071627.

Impactfactor: 6,639

Coignard J, Lush M, Beesley J, O'Mara TA, Dennis J, Tyrer JP, Barnes DR, McGuffog L, Leslie G, Bolla MK, Adank MA, Agata S, Ahearn T, Aittomäki K, Andrulis IL, Anton-Culver H, Arndt V, Arnold N, Aronson KJ, Arun BK, Augustinsson A, Azzollini J, Barrowdale D, Baynes C, Becher H, Bermisheva M, Bernstein L, Białkowska K, Blomqvist C, Bojesen SE, Bonanni B, Borg A, Brauch H, Brenner H, Burwinkel B, Buys SS, Caldés T, Caligo MA, Campa D, Carter BD, Castelao JE, Chang-Claude J, Chanock SJ, Chung WK, Claes KBM, Clarke CL; GEMO Study Collaborators; EMBRACE Collaborators, Collée JM, Conroy DM, Czene K, Daly MB, Devilee P, Diez O, Ding YC, Domchek SM, Dörk T, Dos-Santos-Silva I, Dunning AM, Dwek M, Eccles DM, Eliassen AH, Engel C, Eriksson M, Evans DG, Fasching PA, Flyger H, Fostira F, Friedman E, Fritschi L, Frost D, Gago-Dominguez M, Gapstur SM, Garber J, Garcia-Barberan V, García-Closas M, García-Sáenz JA, Gaudet MM, Gayther SA, Gehrig A, Georgoulas V, Giles GG, Godwin AK, Goldberg MS, Goldgar DE, González-Neira A, Greene MH, Guénel P, Haeberle L, Hahnen E, Haiman CA, Håkansson N, Hall P, Hamann U, Harrington PA, Hart SN, He W, Hogervorst FBL, Hollestelle A, Hopper JL, Horcasitas DJ, Hulick PJ, Hunter DJ, Imyanitov EN; KConFab Investigators; HEBON Investigators ([Siesling S](#)); ABCTB Investigators, Jager A, Jakubowska A, James PA, Jensen UB, John EM, Jones ME, Kaaks R, Kapoor PM, Karlan BY, Keeman R, Khusnutdinova E, Kiiski JI, Ko YD, Kosma VM, Kraft P, Kurian AW, Laitman Y, Lambrechts D, Le Marchand L, Lester J, Lesueur F, Lindstrom T, Lopez-Fernández A, Loud JT, Luccarini C, Mannermaa A, Manoukian S, Margolin S, Martens JWM, Mebirouk N, Meindl A, Miller A, Milne RL, Montagna M, Nathanson KL, Neuhausen SL, Nevanlinna H, Nielsen FC, O'Brien KM, Olopade OI, Olson JE, Olsson H, Osorio A, Ottini L, Park-Simon TW, Parsons MT, Pedersen IS, Peshkin B, Peterlongo P, Peto J, Pharoah PDP, Phillips KA, Polley EC, Poppe B, Presneau N, Pujana MA, Punie K, Radice P, Rantala J, Rashid MU, Rennert G, Rennert HS, Robson M, Romero A, Rossing M, Saloustros E, Sandler DP, Santella R, Scheuner MT, Schmidt MK, Schmidt G, Scott C, Sharma P, Soucy P, Southey MC, Spinelli JJ, Steinsnyder Z, Stone J, Stoppa-Lyonnet D, Swerdlow A, Tamimi RM, Tapper WJ, Taylor JA, Terry MB, Teulé A, Thull DL, Tischkowitz M, Toland AE, Torres D, Trainer AH, Truong T, Tung N, Vachon CM, Vega A, Vijai J, Wang Q, Wappenschmidt B, Weinberg CR, Weitzel JN, Wendt C, Wolk A, Yadav S, Yang XR, Yannoukakos D, Zheng W, Ziogas A, Zorn KK, Park SK, Thomassen M, Offit K, Schmutzler RK, Couch FJ, Simard J, Chenevix-Trench G, Easton DF, Andrieu N, Antoniou AC. [A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers](#). *Nat Commun*. 2021 Feb 17;12(1):1078. doi: 10.1038/s41467-020-20496-3.

Impactfactor: 14,919

Coignard J, Lush M, Beesley J, O'Mara TA, Dennis J, Tyrer JP, Barnes DR, McGuffog L, Leslie G, Bolla MK, Adank MA, Agata S, Ahearn T, Aittomäki K, Andrulis IL, Anton-Culver H, Arndt V, Arnold N, Aronson KJ, Arun BK, Augustinsson A, Azzollini J, Barrowdale D, Baynes C, Becher H, Bermisheva M, Bernstein L, Białkowska K, Blomqvist C, Bojesen SE, Bonanni B, Borg A, Brauch H, Brenner H, Burwinkel B, Buys SS, Caldés T, Caligo MA, Campa D, Carter BD, Castelao JE, Chang-Claude J, Chanock SJ, Chung WK, Claes KBM, Clarke CL; GEMO Study Collaborators; EMBRACE Collaborators, Collée JM, Conroy DM, Czene K, Daly MB, Devilee P, Diez O, Ding YC, Domchek SM, Dörk T, Dos-Santos-Silva I, Dunning AM, Dwek M, Eccles DM, Eliassen AH, Engel C, Eriksson M, Evans DG, Fasching PA, Flyger H, Fostira F, Friedman E, Fritschi L, Frost D, Gago-Dominguez M, Gapstur SM, Garber J, Garcia-Barberan V, García-Closas M, García-Sáenz JA, Gaudet MM, Gayther SA, Gehrig A, Georgoulas V, Giles GG, Godwin AK, Goldberg MS, Goldgar DE, González-Neira A, Greene MH, Guénel P, Haeberle L, Hahnen E, Haiman CA, Håkansson N, Hall P, Hamann U, Harrington PA, Hart SN, He W, Hogervorst FBL, Hollestelle A, Hopper JL, Horcasitas DJ, Hulick PJ, Hunter DJ, Imyanitov EN; KConFab Investigators; HEBON Investigators ([Siesling S](#)); ABCTB Investigators, Jager A, Jakubowska A, James PA, Jensen UB, John EM, Jones ME, Kaaks R, Kapoor PM, Karlan BY, Keeman R, Khusnutdinova E, Kiiski JI, Ko YD, Kosma VM, Kraft P, Kurian AW, Laitman Y, Lambrechts D, Le Marchand L, Lester J, Lesueur F, Lindstrom T, Lopez-Fernández A, Loud JT, Luccarini C, Mannermaa A, Manoukian S, Margolin S, Martens JWM, Mebirouk N, Meindl A, Miller A, Milne RL, Montagna M, Nathanson KL, Neuhausen SL, Nevanlinna H, Nielsen FC, O'Brien KM, Olopade OI, Olson JE, Olsson H, Osorio A, Ottini L, Park-Simon TW, Parsons MT, Pedersen IS, Peshkin B, Peterlongo P, Peto J, Pharoah PDP, Phillips KA, Polley EC, Poppe B, Presneau N, Pujana MA, Punie K, Radice P, Rantala J, Rashid MU, Rennert G, Rennert HS, Robson M, Romero A, Rossing M, Saloustros E, Sandler DP, Santella R, Scheuner MT, Schmidt MK, Schmidt G, Scott C, Sharma P, Soucy P, Southey MC, Spinelli JJ, Steinsnyder Z, Stone J, Stoppa-Lyonnet D, Swerdlow A, Tamimi RM, Tapper WJ, Taylor JA, Terry MB, Teulé A, Thull DL, Tischkowitz M, Toland AE, Torres D, Trainer AH, Truong T, Tung N, Vachon CM, Vega A, Vijai J, Wang Q, Wappenschmidt B, Weinberg CR, Weitzel JN, Wendt C, Wolk A, Yadav S, Yang XR, Yannoukakos D, Zheng W, Ziogas A, Zorn KK, Park SK, Thomassen M, Offit K, Schmutzler RK, Couch FJ, Simard J, Chenevix-Trench G, Easton DF, Andrieu N, Antoniou AC. [Author Correction: A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers.](#) *Nat Commun.* 2021 May 14;12(1):2986. doi: 10.1038/s41467-021-23162-4. Impactfactor: 14,919

[Eijkelboom AH, de Munck L](#), Vrancken Peeters MT, Broeders MJ, Strobbe LJ, Bos ME, Schmidt MK, Guerrero Paez C, Smidt ML, Bessems M, [Verloop J](#), Linn S, Lobbes MBI, Honkoop AH, van den Bongard DH, Westenend PJ, Wesseling J, Menke-van der Houven van Oordt CW, Tjan-Heijnen VC, [Siesling S](#); NABON COVID-19 Consortium and the COVID and Cancer-NL Consortium ([van Hoeve JC, Merks MA](#)). [Impact of the COVID-19 pandemic on diagnosis, stage, and initial treatment of breast cancer in the Netherlands: a population-based study.](#) *J Hematol Oncol.* 2021 Apr 17;14(1):64. doi: 10.1186/s13045-021-01073-7. Impactfactor: 17,388

[Eijkelboom AH, de Munck L](#), Lobbes MB, van Gils CH, Wesseling J, Westenend PJ, Guerrero Paez C, Pijnappel RM, Verkooijen HM, Broeders MJ, [Siesling S](#); NABON COVID-19 Consortium and the COVID and Cancer-NL Consortium. [Impact of the suspension and restart of the Dutch breast cancer screening program on breast cancer incidence and stage during the COVID-19 pandemic.](#) *Prev Med.* 2021 Oct; 151:106602. doi: 10.1016/j.ypmed.2021.106602. Epub 2021 Jun 30. Impactfactor: 4,018

Filipe MD, [Siesling S](#), Vriens MR, van Diest P, Witkamp AJ. [The association of socioeconomic status on treatment strategy in patients with stage I and II breast cancer in the Netherlands.](#) *Breast Cancer Res Treat.* 2021 Jun 26. doi: 10.1007/s10549-021-06308-2. Online ahead of print. Impactfactor: 4,872

Gal R, van Velzen SG, Hooning MJ, Emaus MJ, van der Leij F, Gregorowitsch ML, Blezer EL, Gernaat SA, Lessmann N, Sattler MG, Leiner T, de Jong PA, Teske AJ, [Verloop J](#), Penninkhof JJ, Vaartjes I, Meijer H, van Tol-Geerdink JJ, Pignol JP, van den Bongard DH, Išgum I, Verkooijen HM. [Identification of risk of cardiovascular disease by automatic quantification of coronary artery calcifications on radiotherapy planning CT scans in patients with breast cancer.](#) *JAMA Oncol.* 2021 May 6. doi: 10.1001/jamaoncol.2021.1144. Online ahead of print. Impactfactor: 31,8

Gommers JJ, **Voogd AC**, Broeders MJ, van Breest Smalenburg V, Strobbe LJ, Donkers-van Rossum AB, van Beek HC, Mann RM, Duijm LE. Breast magnetic resonance imaging as a problem solving tool in women recalled at biennial screening mammography: a population-based study in the Netherlands. *Breast*. 2021 Nov 20;60:279-286. doi: 10.1016/j.breast.2021.11.014. Online ahead of print. Impactfactor: 4,38

Groen WG, Naaktgeboren WR, van Harten WH, van Vulpen JK, Kool N, Sonke GS, van der Wall E, **Velthuis MJ**, Aaronson NK, May AM, Stuiver MM. Physical fitness and chemotherapy tolerance in patients with early-stage breast cancer. *Med Sci Sports Exerc*. 2021 Dec 27. doi: 10.1249/MSS.0000000000002828. Online ahead of print. Impactfactor: 5,411

Heins MJ, **de Ligt KM**, **Verloop J**, **Siesling S**, Korevaar JC; PSCCR group. Adverse health effects after breast cancer up to 14 years after diagnosis. *Breast*. 2021 Dec 3;61:22-28. doi: 10.1016/j.breast.2021.12.001. Online ahead of print. Impactfactor: 4,38

Lameijer JR, **Voogd AC**, Broeders MJ, Pijnappel RM, Setz-Pels W, Strobbe LJ, Jansen FH, Tjan-Heijnen VC, Duijm LE. Trends in delayed breast cancer diagnosis after recall at screening mammography. *Eur J Radiol*. 2021 Jan 2;136:109517. doi: 10.1016/j.ejrad.2020.109517. Online ahead of print. Impactfactor: 3,528

Luiten JD, Luiten EJ, van der Sangen MJ, Vreuls W, Duijm LE, Tjan-Heijnen VC, **Voogd AC**. Patterns of treatment and outcome of ductal carcinoma in situ in the Netherlands. *Breast Cancer Res Treat*. 2021 Jan 1. doi: 10.1007/s10549-020-06055-w. Online ahead of print. Impactfactor: 4,872

Moncada-Torres A, **van Maaren MC**, **Hendriks MP**, **Siesling S**, **Geleijnse G**. Explainable machine learning can outperform Cox regression predictions and provide insights in breast cancer survival. *Sci Rep*. 2021 Mar 26;11(1): 6968. doi: 10.1038/s41598-021-86327-7. Impactfactor: 4,38

Moosdorff M, Vane ML, van Nijnatten TJ, **van Maaren MC**, Goorts B, Heuts EM, Strobbe LJ, Smidt ML. Conditional local recurrence risk: the effect of event-free years in different subtypes of breast cancer. *Breast Cancer Res Treat*. 2021 Mar 10. doi: 10.1007/s10549-020-06040-3. Online ahead of print. Impactfactor: 4,872

Ploumen RA, Keymeulen KB, Kooreman LF, van Kuijk SM, **Siesling S**, Smidt ML, van Nijnatten TJ. The percentage of residual DCIS in patients diagnosed with primary invasive breast cancer treated with neoadjuvant systemic therapy: a nationwide retrospective study. *Eur J Surg Oncol*. 2021 Oct 22:S0748-7983(21)00765-4. doi: 10.1016/j.ejso.2021.10.016. Online ahead of print. Impactfactor: 4,424

Schermers B, van Riet YE, Schipper RJ, Vrancken Peeters MJ, **Voogd AC**, Nieuwenhuijzen GA, Ten Haken B, Ruers TJ. Nationwide registry study on trends in localization techniques and reoperation rates in non-palpable ductal carcinoma in situ and invasive breast cancer. *Br J Surg*. 2021 Oct 13:znab339. doi: 10.1093/bjs/znab339. Impactfactor: 6,939

Schipper RJ, de Bruijn A, **Voogd AC**, Bloemen JG, Van Riet YE, Vriens BE, Smidt ML, **Siesling S**, van der Sangen MJ, Nieuwenhuijzen GA. Rate and predictors of nodal pathological complete response following neoadjuvant endocrine treatment in clinically biopsy-proven node-positive breast cancer patients. *Eur J Surg Oncol*. 2021 May 18:S0748-7983(21)00474-1. doi: 10.1016/j.ejso.2021.04.041. Online ahead of print. Impactfactor: 4,424

Steenbruggen TG, Schaapveld M, Horlings HM, Sanders J, **Hogewoning SJ**, Lips EH, Vrancken Peeters MT, Kok NF, Wiersma T, Esserman L, van 't Veer LJ, Linn SC, **Siesling S**, Sonke GS. Characterization of oligometastatic disease in a real-world nationwide cohort of 3447 patients with de novo metastatic breast cancer. *JNCI Cancer Spectr.* 2021 Feb 4;5(3):pkab010. doi: 10.1093/jncics/pkab010. eCollection 2021 Jun.

Impactfactor: 0,58

van Cappellen-van Maldegem SJ, **Mols F**, **Horevoorts N**, de Kruif A, Buffart LM, Schoormans D, Trompetter H, **Beijer S**, **Ezendam NP**, de Boer M, Winkels R, Kampman E, Schuit J, **van de Poll-Franse LV**, Seidell JC, Hoedjes M; OPTIMUM research team. Towards OPTimal Timing and Method for promoting sUstained adherence to lifestyle and body weight recommendations in postMenopausal breast cancer survivors (the OPTIMUM-study): protocol for a longitudinal mixed-method study. *BMC Womens Health.* 2021 Jul 6;21(1):268. doi: 10.1186/s12905-021-01406-1.

Impactfactor: 2,809

van Dooijeweert C, Baas IO, Deckers IA, **Siesling S**, van Diest PJ, van der Wall E. The increasing importance of histologic grading in tailoring adjuvant systemic therapy in 30,843 breast cancer patients. *Breast Cancer Res Treat.* 2021 Jan 30. doi: 10.1007/s10549-021-06098-7. Online ahead of print.

Impactfactor: 4,872

van Egdom LS, de Ligt KM, **de Munck L**, Koppert LB, Mureau MA, Rakhorst HA, **Siesling S**. Predictors of delayed breast reconstruction in the Netherlands: a 5-year follow-up study in stage I-III breast cancer patients. *Breast Cancer.* 2021 Nov 15. doi: 10.1007/s12282-021-01313-1. Online ahead of print.

Impactfactor: 4,239

van Maaren MC, **Ávila AO**, **van Manen JG**, Menke-Pluijmers MB, Veltman J, Bart J, Westenend PJ, **Siesling S**. Trends in incidence, treatment, survival and subsequent breast cancer in lobular carcinoma in situ in the Netherlands: a population-based analysis. *Breast.* 2021 Aug 3;59:376-382. doi: 10.1016/j.breast.2021.07.020. Online ahead of print.

Impactfactor: 4,380

van Seijen M, Lips EH, Fu L, Giardiello D, van Duijnhoven F, **de Munck L**, Elshof LE, Thompson A, Sawyer E, Ryser MD, Hwang ES, Schmidt MK, Elkhuizen PH; Grand Challenge PRECISION Consortium, Wesseling J, Schaapveld M. Long-term risk of subsequent ipsilateral lesions after surgery with or without radiotherapy for ductal carcinoma in situ of the breast. *Br J Cancer.* 2021 Aug 18. doi: 10.1038/s41416-021-01496-6. Online ahead of print.

Impactfactor: 7,640

Voets MM, Groothuis-Oudshoorn CG, Veneklaas LH, Manohar S, Brinkhuis M, Veltman J, **de Munck L**, de Geus-Oei LF, Broeders MJ, **Siesling S**. Diagnostics in patients suspect for breast cancer in The Netherlands. *Curr Oncol.* 2021 Nov 29;28(6):4998-5008. doi: 10.3390/curroncol28060419.

Impactfactor: 3,677

Völkel V, Hueting TA, Draeger T, **van Maaren MC**, **de Munck L**, Strobbe LJ, Sonke GS, Schmidt MK, van Hezewijk M, Groothuis-Oudshoorn CG, **Siesling S**. Improved risk estimation of locoregional recurrence, secondary contralateral tumors and distant metastases in early breast cancer: the INFLUENCE 2.0 model. *Breast Cancer Res Treat.* 2021 Aug 2. doi: 10.1007/s10549-021-06335-z.

Impactfactor: 4,872

Walstra CJ, Schipper RJ, van Riet YE, van der Toorn PG, Smidt ML, Sangen MJ, **Voogd AC**, Nieuwenhuijzen GA. Repeat breast-conserving treatment of ipsilateral breast cancer recurrence: a nationwide survey amongst breast surgeons and radiation oncologists in the Netherlands. *Breast Cancer Res Treat.* 2021 Mar 13. doi: 10.1007/s10549-021-06154-2.

Impactfactor: 4,872

2.2 Overige publicaties

Wolbers R, Bode C, Siemerink E, **Siesling S**, Pieterse M. Cognitive bias modification training to improve implicit vitality in patients with breast cancer: app design using a cocreation approach. *JMIR Form Res.* 2021 Mar 10;5(3):e18325. doi: 10.2196/18325.

3 Bot-en wekedelentumoren

3.1 Publicaties met impactfactor

Drabbe C, van der Graaf WT, **de Rooij BH**, Grünhagen DJ, Soomers VL, van de Sande MA, Been LB, Keymeulen KB, van der Geest IC, van Houdt WJ, Husson O. [The age-related impact of surviving sarcoma on health-related quality of life: data from the SURVSARC study](#). *ESMO Open*. 2021 Jan 27;6(1):100047. doi: 10.1016/j.esmoop.2021.100047. Online ahead of print. Impactfactor: 6,54

Husson O, Weidema M, Leonard H, Hartle DeYoung L, van der Graaf W, **van de Poll-Franse LV**. [Supportive care needs of patients living with an extremely rare and unpredictable cancer: the epithelioid haemangioendothelioma patient experience](#). *Eur J Cancer Care (Engl)*. 2021 May 14:e13461. doi: 10.1111/ecc.13461. Online ahead of print. Impactfactor: 2,52

Melis AS, Vos M, **Schuurman MS**, van Dalen T, van Houdt WJ, van der Hage JA, Schrage YM, Been LB, Bonenkamp JB, Bemelmans MH, Grünhagen DJ, Verhoef C, **Ho VK**; Dutch Sarcoma Group (DSG). [Incidence of unplanned excisions of soft tissue sarcomas in the Netherlands: a population-based study](#). *Eur J Surg Oncol*. 2021 Nov 19:S0748-7983(21)00932-X. doi: 10.1016/j.ejso.2021.11.123. Online ahead of print. Impactfactor: 4,424

Stacchiotti S, Frezza AM, Blay JY, Baldini EH, Bonvalot S, Bovée JV, Callegaro D, Casali PG, Chiang RC, Demetri GD, Demicco EG, Desai J, Eriksson M, Gelderblom H, George S, Gounder MM, Gronchi A, Gupta A, Haas RL, Hayes-Jardon A, Hohenberger P, Jones KB, Jones RL, Kasper B, Kawai A, Kirsch DG, Kleinerman ES, Le Cesne A, Lim J, Chirlaque López MD, Maestro R, Marcos-Gragera R, Martin Broto J, Matsuda T, Mir O, Patel SR, Raut CP, Razak AR, Reed DR, Rutkowski P, Sanfilippo RG, Sbaraglia M, Schaefer IM, Strauss DC, Sundby Hall K, Tap WD, Thomas DM, van der Graaf WT, van Houdt WJ, **Visser O**, von Mehren M, Wagner AJ, Wilky BA, Won YJ, Fletcher CD, Dei Tos AP, Trama A. [Ultra-rare sarcomas: a consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities](#). *Cancer*. 2021 Apr 28. doi: 10.1002/cncr.33618. Online ahead of print. Impactfactor: 6,86

3.2 Overige publicaties

van Meekeren M, Fiocco M, **Ho VK**, Bovée JV, Gelderblom H, Haas RL. [Patterns of perioperative treatment and survival of localized, resected, intermediate- or high-grade soft tissue sarcoma: a 2000-2017 Netherlands Cancer Registry database analysis](#). *Sarcoma*. 2021 Jul 22;2021:9976122. doi: 10.1155/2021/9976122.

4 Darmkanker

4.1 Publicaties met impactfactor

Bahadoer RR, Bastiaannet E, Claassen YH, **van der Mark M**, van Eycken E, Verbeeck J, Guren MG, Kørner H, Martling A, Johansson R, van de Velde CJ, Dekker JW. One-year excess mortality and treatment in surgically treated patients with colorectal cancer: a EURECCA European comparison. *Eur J Surg Oncol*. 2021 Jan 21:S0748-7983(21)00037-8. doi: 10.1016/j.ejso.2021.01.011. Online ahead of print. Impactfactor: 4,424

Bakkers C, **Lurvink RJ, van Erning FN**, Nienhuijs SW, **de Hingh IH**. ASO author reflections: treatment and prognosis of colorectal peritoneal metastases. *Ann Surg Oncol*. 2021 Jun 5. doi: 10.1245/s10434-021-10265-x. Online ahead of print. Impactfactor: 5,344

Bakkers C, **Lurvink RJ**, Rijken A, Nienhuijs SW, Kok NF, Creemers GJ, Verhoef C, **Lemmens VE, van Erning FN, de Hingh IH**. ASO visual abstract: treatment strategies and prognosis in patients with synchronous or metachronous colorectal peritoneal metastases: a population-based study. *Ann Surg Oncol*. 2021 Jul 13. doi: 10.1245/s10434-021-10253-1. Online ahead of print. Impactfactor: 5,344

Bakkers C, **Lurvink RJ**, Rijken A, Nienhuijs SW, Kok NF, Creemers GJ, Verhoef C, **Lemmens VE, van Erning FN, de Hingh IH**. Treatment strategies and prognosis of patients with synchronous or metachronous colorectal peritoneal metastases: a population-based study. *Ann Surg Oncol*. 2021 Jun 2. doi: 10.1245/s10434-021-10190-z. Online ahead of print. Impactfactor: 5,344

Bonhof CS, van de Poll-Franse LV, de Hingh IH, Nefs G, Vreugdenhil G, **Mols F**. Association between peripheral neuropathy and sleep quality among colorectal cancer patients from diagnosis until 2-year follow-up: results from the PROFILES registry. *J Cancer Surviv*. 2021 Nov 19. doi: 10.1007/s11764-021-01130-7. Online ahead of print. Impactfactor: 4,442

Breekveldt EC, Lansdorp-Vogelaar I, Toes-Zoutendijk E, Spaander MC, van Vuuren AJ, van Kemenade FJ, Ramakers CR, Dekker E, Nagtegaal ID, Krul MF, Kok NF, Kuhlmann KF, **Vink GR**, van Leerdam ME, **Eiferink MA**; Dutch National Colorectal Cancer Screening Working Group. Colorectal cancer incidence, mortality, tumour characteristics, and treatment before and after introduction of the faecal immunochemical testing-based screening programme in the Netherlands: a population-based study. *Lancet Gastroenterol Hepatol*. 2021 Nov 22:S2468-1253(21)00368-X. doi: 10.1016/S2468-1253(21)00368-X. Online ahead of print. Impactfactor: 18,486

Cardoso R, Guo F, Heisser T, Hackl M, Ihle P, De Schutter H, Van Damme N, Valerianova Z, Atanasov T, Májek O, Mužík J, Nilbert MC, Tybjerg AJ, Innos K, Mägi M, Malila N, Bouvier AM, Bouvier V, Launoy G, Woronoff AS, Cariou M, Robaszkiewicz M, Delafosse P, Poncet F, Katalinic A, Walsh PM, Senore C, Rosso S, Vincerževskienė I, **Lemmens VE, Eiferink MA**, Johannesen TB, Kørner H, Pfeffer F, Bento MJ, Rodrigues J, Alves da Costa F, Miranda A, Zadnik V, Žagar T, Lopez de Munain Marques A, Marcos-Gragera R, Puigdemont M, Galceran J, Carulla M, Chirlaque MD, Ballesta M, Sundquist K, Sundquist J, Weber M, Jordan A, Herrmann C, Mousavi M, Ryzhov A, Hoffmeister M, Brenner H. Colorectal cancer incidence, mortality, and stage distribution in European countries in the colorectal cancer screening era: an international population-based study. *Lancet Oncol*. 2021 May 25:S1470-2045(21)00199-6. doi: 10.1016/S1470-2045(21)00199-6. Online ahead of print. Impactfactor: 41,316

de Haan-Du J, Landman GW, Kleefstra N, Schrijnders D, Manders M, **Bos AC**, Tromp-van Driel C, Denig P, Groenier KH, de Bock GH. Glycemic control for colorectal cancer survivors compared to those without cancer in the Dutch primary care for type 2 diabetes: a prospective cohort study. *Cancers (Basel)*. 2021 Jun 2;13(11):2767. doi: 10.3390/cancers13112767. Impactfactor: 6,639

de Hingh IH. Heated intraperitoneal chemotherapy for colorectal cancer: game over or game on? *Br J Surg*. 2021 May 10;znab156. doi: 10.1093/bjs/znab156. Online ahead of print. PMID: 33970225 No abstract available.
Impactfactor: 6,939

de Nes LC, van der Heijden JA, Verstegen MG, Drager L, Tanis PJ, **Verhoeven RH**, de Wilt JH. Predictors of undergoing multivisceral resection, margin status and survival in Dutch patients with locally advanced colorectal cancer. *Eur J Surg Oncol*. 2021 Nov 6:S0748-7983(21)00789-7. doi: 10.1016/j.ejso.2021.11.004. Online ahead of print.
Impactfactor: 4,424

de Wind A, Tamminga SJ, Bony CA, Diether M, Ludwig M, **Velthuis MJ, Duijts SF**, de Boer AG. Loss of paid employment up to 4 years after colorectal cancer diagnosis: a nationwide register-based study with a population-based reference group. *Cancers (Basel)*. 2021 Jun 8;13(12):2868. doi: 10.3390/cancers13122868.
Impactfactor: 6,639

de Winter J, **Ezendam NP**, Bours MJ, Winkels RM, Weijenberg MP, Kampman E, **Vissers PA, Mols F, Beijer S**. Is sleep associated with BMI, waist circumference, and diet among long-term colorectal cancer survivors? Results from the population-based PROFILES registry. *Support Care Cancer*. 2021 Jul 6. doi: 10.1007/s00520-021-06393-5. Online ahead of print.
Impactfactor: 3,603

Derksen JW, May AM, **van de Poll-Franse LV, de Rooij BH**, Hafkenscheid DA, Verkooijen HM, Koopman M, **Vink GR**. Colorectal cancer care and patients' perceptions before and during COVID-19: implications for subsequent SARS-CoV-2 infection waves. *JNCI Cancer Spectr*. 2021 May 13;5(4):pkab047. doi: 10.1093/jncics/pkab047. eCollection 2021 Aug.
Impactfactor: 0,58

Derksen JW, **Vink GR, Elferink MA**, Roodhart JM, Verkooijen HM, van Grevenstein WM, Siersema PD, May AM, Koopman M; PLCRC Study Group. The Prospective Dutch Colorectal Cancer (PLCRC) cohort: real-world data facilitating research and clinical care. *Sci Rep*. 2021 Feb 16;11(1):3923. doi: 10.1038/s41598-020-79890-y.
Impactfactor: 4,38

Franken MD, **Vink GR**, van Grevenstein WM, Verkooijen HM, Punt CJ, Koopman M, May AM; PLCRC study group*. Work ability in patients with stage I-IV colon cancer: results of the Dutch prospective colorectal cancer cohort. *Dis Colon Rectum*. 2021 Oct 21. doi: 10.1097/DCR.0000000000002075. Online ahead of print.
Impactfactor: 4,785

Giesen LJ, Olthof PB, **Elferink MA**, van Westreenen HL, Beets GL, Verhoef C, Dekker JW. Changes in rectal cancer treatment after the introduction of a national screening program; Increasing use of less invasive strategies within a national cohort. *Eur J Surg Oncol*. 2021 Dec 1:S0748-7983(21)00941-0. doi: 10.1016/j.ejso.2021.11.132. Online ahead of print.
Impactfactor: 4,424

Giesen LJ, Olthof PB, **Elferink MA**, Verhoef C, Dekker JW. Surgery for rectal cancer: differences in resection rates among hospitals in the Netherlands. *Eur J Surg Oncol*. 2021 Apr 28:S0748-7983(21)00458-3. doi: 10.1016/j.ejso. 2021.04.030. Online ahead of print.
Impactfactor: 4,424

Hommes S, Vromans R, Clouth F, Verbeek X, de Hingh I, Krahmer E. Communication in decision aids for stage I-III colorectal cancer patients: a systematic review. *BMJ Open*. 2021 Apr 29;11(4):e044472. doi: 10.1136/bmjopen-2020-044472.
Impactfactor: 2,692

Jongeneel G, Greuter MJ, Kunst N, **van Erning FN**, Koopman M, Medema JP, Vermeulen L, Ijzermans JN, **Vink GR**, Punt CJ, Coupé VM. Early cost-effectiveness analysis of risk-based selection strategies for adjuvant treatment in stage II colon cancer: the potential value of prognostic molecular markers. *Cancer Epidemiol Biomarkers Prev.* 2021 Jun 23;cebp.0078.2021. doi: 10.1158/1055-9965.EPI-21-0078. Online ahead of print.
Impactfactor: 4,254

Jongeneel G, Greuter MJ, **van Erning FN**, Twisk JW, Koopman M, Punt CJ, **Vink GR**, Coupé VM. Longitudinal effects of adjuvant chemotherapy and related neuropathy on health utility in stage II and III colon cancer patients: a prospective cohort study. *Int J Cancer.* 2021 Jan 18. doi: 10.1002/ijc.33472. Online ahead of print.
Impactfactor: 7,396

Jongeneel G, Greuter MJ, **van Erning FN**, Koopman M, **Vink GR**, Punt CJ, Coupé VM. Model-based effectiveness and cost-effectiveness of risk-based selection strategies for adjuvant chemotherapy in Dutch stage II colon cancer patients. *Therap Adv Gastroenterol.* 2021 Mar 12;14:1756284821995715. doi: 10.1177/1756284821995715. eCollection 2021.
Impactfactor: 4,409

Keikes L, **Kos M**, **Verbeek XA**, **van Vegchel T**, Nagtegaal ID, Lahaye MJ, Méndez Romero A, de Bruijn S, Verheul HM, Rütten H, Punt CJ, Tanis PJ, **van Oijen MG**. Conversion of a colorectal cancer guideline into clinical decision trees with assessment of validity. *Int J Qual Health Care.* 2021 Mar 24:mzab051. doi: 10.1093/intqhc/mzab051.
Impactfactor: 2,038

Koëter T, de Nes LC, Wasowicz DK, Zimmerman DD, **Verhoeven RH**, **Elferink MA**, de Wilt JH. Hospital variation in sphincter-preservation rates in rectal cancer treatment: results of a population-based study in the Netherlands. *BJS Open.* 2021 Jul 6;5(4):zrab065. doi: 10.1093/bjsopen/zrab065.
Impactfactor: 3,396

Kuiper JG, van Herk-Sukel MP, **Lemmens VE**, Kuipers EJ, Herings RM. A steep increase in healthcare seeking behaviour in the last months before colorectal cancer diagnosis. *BMC Fam Pract.* 2021 Jun 21;22(1):121. doi: 10.1186/s12875-021-01482-0.
Impactfactor: 2,497

Kuiper JG, Fenneman AC, van der Spek AH, Rampanelli E, Nieuwdorp M, van Herk-Sukel MP, **Lemmens VE**, Kuipers EJ, Herings RM, Fliers E. Levothyroxine use and the risk of colorectal cancer: a large population-based case-control study. *Endocr Connect.* 2021 Dec 1:EC-21-0463.R1. doi: 10.1530/EC-21-0463. Online ahead of print.
Impactfactor: 3,335

Lurvink RJ, Rovers KP, Wassenaar EC, Bakkers C, Burger JW, Creemers GM, Los M, **Mols F**, Wiezer MJ, Nienhuijs SW, Boerma D, **de Hingh IH**. Patient-reported outcomes during repetitive oxaliplatin-based pressurized intraperitoneal aerosol chemotherapy for isolated unresectable colorectal peritoneal metastases in a multicenter, single-arm, phase 2 trial (CRC-PIPAC). *Surg Endosc.* 2021 Nov 10. doi: 10.1007/s00464-021-08802-6. Online ahead of print.
Impactfactor: 4,584

Meyer Y, Olthof PB, Grünhagen DJ, de Hingh I, de Wilt JH, Verhoef C, **Elferink MA**. Treatment of metachronous colorectal cancer metastases in the Netherlands: a population-based study. *Eur J Surg Oncol.* 2021 Dec 4:S0748-7983(21)00951-3. doi: 10.1016/j.ejso.2021.12.004. Online ahead of print.
Impactfactor: 4,424

Qaderi SM, Galjart B, Verhoef C, Slooter GD, Koopman M, **Verhoeven RH**, de Wilt JH, **van Erning FN**. Disease recurrence after colorectal cancer surgery in the modern era: a population-based study. *Int J Colorectal Dis.* 2021 Apr 4. doi: 10.1007/s00384-021-03914-w. Online ahead of print.
Impactfactor: 2,571

Qaderi SM, **Ezendam NP**, **Verhoeven RH**, Custers JA, de Wilt JH, **Mols F**. Follow-up practice and healthcare utilisation of colorectal cancer survivors. *Eur J Cancer Care (Engl)*. 2021 Jun 3:e13472. doi: 10.1111/ecc.13472. Online ahead of print. Impactfactor: 2,52

Qaderi SM, Andersson TM, Dickman PW, de Wilt JH, **Verhoeven RH**. Temporal improvements noted in life expectancy of patients with colorectal cancer: a Dutch population-based study. *J Clin Epidemiol*. 2021 Apr 6:S0895-4356(21)00106-2. doi: 10.1016/j.jclinepi.2021.03.024. Online ahead of print. Impactfactor: 6,473

Qaderi SM, van der Heijden JA, **Verhoeven RH**, de Wilt JH, Custers JA; PLCRC study group. Trajectories of health-related quality of life and psychological distress in patients with colorectal cancer: a population-based study. *Eur J Cancer*. 2021 Oct 16;158:144-155. doi: 10.1016/j.ejca.2021.08.050. Online ahead of print. Impactfactor: 9,162

Ramp D, **Mols F**, **Ezendam N**, **Beijer S**, Bours M, Winkels R, de Vries J, Seidell JC, Kampman E, Hoedjes M. Psychological distress and lower health-related quality of life are associated with need for dietary support among colorectal cancer survivors with overweight or obesity. *Support Care Cancer*. 2021 Jun 17. doi: 10.1007/s00520-021-06306-6. Online ahead of print. Impactfactor: 3,603

Reudink M, Molenaar CJ, **Bonhof CS**, Janssen L, **Mols F**, Slooter GD. Evaluating the longitudinal effect of colorectal surgery on health-related quality of life in patients with colorectal cancer. *J Surg Oncol*. 2021 Sep 27. doi: 10.1002/jso.26685. Online ahead of print. Impactfactor: 3,454

Révész D, Bours MJL, Wegdam JA, Keulen ETP, Breukink SO, Slooter GD, Vogelaar FJ, Weijenberg MP, **Mols F**. Associations between alcohol consumption and anxiety, depression, and health-related quality of life in colorectal cancer survivors. *J Cancer Surviv*. 2021 Sep 16. doi: 10.1007/s11764-021-01090-y. Impactfactor: 4,442

Révész D, Bours MJ, Wegdam JA, Keulen ET, Breukink SO, Slooter GD, Vogelaar FJ, Weijenberg MP, **Mols F**. Longitudinal associations of sociodemographic, lifestyle, and clinical factors with alcohol consumption in colorectal cancer survivors up to 2 years post-diagnosis. *Support Care Cancer*. 2021 Mar 24. doi: 10.1007/s00520-021-06104-0. Impactfactor: 3,603

Rovers KP, Bakkens C, Nienhuijs SW, Burger JW, Creemers GM, Thijs AM, Brandt-Kerkhof AR, Madsen EV, van Meerten E, Tuynman JB, Kusters M, Versteeg KS, Aalbers AG, Kok NF, Buffart TE, Wiezer MJ, Boerma D, Los M, de Reuver PR, Bremers AJ, Verheul HM, Kruijff S, de Groot DJ, Witkamp AJ, van Grevenstein WM, Koopman M, Nederend J, Lahaye MJ, Kranenburg O, Fijneman RJ, van 't Erve I, Snaebjornsson P, Hemmer PH, Dijkgraaf MG, Punt CJ, Tanis PJ, de Hingh IH. Dutch Peritoneal Oncology Group and the Dutch Colorectal Cancer Group (**Bouma J**). Perioperative systemic therapy vs cytoreductive surgery and hyperthermic intraperitoneal chemotherapy alone for resectable colorectal peritoneal metastases: a phase 2 randomized clinical trial. *JAMA Surg*. 2021 Aug 1;156(8):710-720. doi: 10.1001/jamasurg.2021.1642. Impactfactor: 14,766

Schoormans D, van Es B, **Mols F**, Wasowicz D, **Beijer S**, **Ezendam NP**. The relation between sleep quality, sleep quantity, and gastrointestinal problems among colorectal cancer survivors: result from the PROFILES registry. *Support Care Cancer*. 2021 Sep 14. doi: 10.1007/s00520-021-06531-z. Online ahead of print. Impactfactor: 3,603

Steeghs EM, **Vink GR**, **Elferink MA**, Voorham QJM, Gelderblom H, Nagtegaal ID; PATH Consortium Members, Grünberg K, Ligtenberg MJ; PATH consortium members. Nationwide evaluation of mutation-tailored anti-EGFR therapy selection in patients with colorectal cancer in daily clinical practice. *J Clin Pathol*. 2021 Oct 21:jclinpath-2021-207865. doi: 10.1136/jclinpath-2021-207865. Online ahead of print. Impactfactor: 3,411

Toes-Zoutendijk E, **Vink G**, Nagtegaal ID, Spaander MC, Dekker E, van Leerdam ME, **Siesling S**, Lansdorp-Vogelaar I, **Elferink MA**; COVID and Cancer-NL consortium. Impact of COVID-19 and suspension of colorectal cancer screening on incidence and stage distribution of colorectal cancers in the Netherlands. *Eur J Cancer*. 2021 Nov 24;161:38-43. doi: 10.1016/j.ejca.2021.11.008. Online ahead of print.

Impactfactor: 9,162

Trompetter HR, **Bonhof CS**, **van de Poll-Franse LV**, Vreugdenhil G, **Mols F**. Exploring the relationship among dispositional optimism, health-related quality of life, and CIPN severity among colorectal cancer patients with chronic peripheral neuropathy. *Support Care Cancer*. 2021 Jul 7. doi: 10.1007/s00520-021-06352-0. Online ahead of print.

Impactfactor: 3,603

van der Heijden JA, Qaderi SM, **Verhoeven RH**, Custers JA, Klarenbeek BR, Maaskant-Braat AJ, de Wilt JH. Transanal total mesorectal excision and low anterior resection syndrome. *Br J Surg*. 2021 Apr 9;znab056. doi: 10.1093/bjs/znab056. Online ahead of print.

Impactfactor: 6,939

van der Kruijssen DE, Brouwer NP, van der Kuil AJ, **Verhoeven RH**, Elias SG, **Vink GR**, Punt CJ, de Wilt JH, Koopman M. Interaction between primary tumor resection, primary tumor location, and survival in synchronous metastatic colorectal cancer: a population-based study. *Am J Clin Oncol*. 2021 Apr 23. doi: 10.1097/JCO.0000000000000823. Online ahead of print.

Impactfactor: 2,339

van der Kruijssen DE, van Rooijen KL, Kurk SA, de Wilt JH, Punt CJ, **Vink GR**, Elias SG, Koopman M. Role of up-front primary tumor resection and tumor sidedness in the survival of synchronous metastatic colon cancer patients. *Dig Surg*. 2021 Jul 28:1-7. doi: 10.1159/000517477. Online ahead of print.

Impactfactor: 2,588

van der Kruijssen DE, Elias SG, **Vink GR**, van Rooijen KL, 't Lam-Boer J, **Mol L**, Punt CJ, de Wilt JH, Koopman M; CAIRO4 Working Group. Sixty-day mortality of patients with metastatic colorectal cancer randomized to systemic treatment vs primary tumor resection followed by systemic treatment: the CAIRO4 Phase 3 randomized clinical trial. *JAMA Surg*. 2021 Oct 6. doi: 10.1001/jamasurg.2021.4992.

Impactfactor: 14,766

van der Vlies E, Vernooij LM, Hamaker ME, van der Velden AM, Smits M, Intven MP, van Dodewaard JM, Takkenberg M, **Vink GR**, Smits AB, Bos WJ, van Dongen EP, Los M, Noordzij PG. Frailty and health related quality of life three months after non-metastatic colorectal cancer diagnosis in older patients: a multi-centre prospective observational study. *J Geriatr Oncol*. 2021 Aug 23:S1879-4068(21)00179-X. doi: 10.1016/j.jgo.2021.08.005. Online ahead of print.

Impactfactor: 3,599

van der Vlies E, Vernooij LM, **van Erning FN**, **Vink GR**, Bos WJ, Portielje JE, Noordzij PG, Los M. Survival of surgical and non-surgical older patients with non-metastatic colorectal cancer: a population-based study in the Netherlands. *Eur J Surg Oncol*. 2021 Jul 26:S0748-7983(21)00639-9. doi: 10.1016/j.ejso.2021.07.018. Online ahead of print.

Impactfactor: 4,424

van Herwaarden YJ, **Madani A**, van der Post RS, **Lemmens VE**, Nagtegaal ID. Incidental diagnosis of serrated polyp in the appendix warrants colonoscopy to screen for colorectal neoplasia. *Br J Surg*. 2021 Sep 11;znab305. doi: 10.1093/bjs/znab305. Online ahead of print.

Impactfactor: 6,939

van Loon YT, **van Erning FN**, Maas HA, Stassen LP, Zimmerman DD. Primary anastomosis versus endostomy in left-sided colonic and proximal rectal cancer surgery in the elderly Dutch population: a propensity score matched analysis. *Ann Surg Oncol*. 2021 Apr 25. doi: 10.1245/s10434-021-09976-y. Online ahead of print.

Impactfactor: 5,344

van Nassau SC, Bond MJ, Scheerman I, van Breeschoten J, Kessels R, Valkenburg-van Iersel LB, Verheul HM, Buffart TE, Mekenkamp LJ, **Lemmens VE**, Koopman M, Bol GM; EXCITE (From Clinical Trial to Bedside: Triplet Chemotherapy in Metastatic Colorectal Cancer) Study Group. Trends in use and perceptions about triplet chemotherapy plus bevacizumab for metastatic colorectal cancer. *JAMA Netw Open*. 2021 Sep 1;4(9):e2124766. doi: 10.1001/jamanetworkopen.2021.24766. Impactfactor: 8,483

van Rees JM, **Elferink MA**, Tanis PJ, de Wilt JH, Burger JW, Verhoef C. The incidence, treatment and survival of patients with rare types of rectal malignancies in the Netherlands: a population-based study between 1989 and 2018. *Eur J Cancer*. 2021 Jun 8;152:183-192. doi: 10.1016/j.ejca.2021.04.036. Online ahead of print. Impactfactor: 9,162

Verseveld M, Verver D, Noordman BJ, Pouwels S, **Elferink MA**, de Graaf EJ, Verhoef C, Doornebosch PG, de Wilt JH. Treatment of clinical T1 rectal cancer in the Netherlands; a population-based overview of clinical practice. *Eur J Surg Oncol*. 2021 Nov 13:S0748-7983(21)00787-3. doi: 10.1016/j.ejso.2021.11.002. Online ahead of print. Impactfactor: 4,424

Wensink E, Bond M, Kucukkose E, May A, **Vink GR**, Koopman M, Kranenburg O, Roodhart J. A review of the sensitivity of metastatic colorectal cancer patients with deficient mismatch repair to standard-of-care chemotherapy and monoclonal antibodies, with recommendations for future research. *Cancer Treat Rev*. 2021 Mar 1;95:102174. doi: 10.1016/j.ctrv.2021.102174. Impactfactor: 12,111

5 Gynaecologische tumoren

5.1 Publicaties met impactfactor

Baldewpersad Tewarie NM, van Driel WJ, van Ham M, Wouters MW, Kruitwagen R; participants of the Dutch Gynecological Oncology Collaborator Group ([van der Aa MA](#)). Clinical auditing as an instrument to improve care for patients with ovarian cancer: the Dutch Gynecological Oncology Audit (DGOA). *Eur J Surg Oncol*. 2021 Feb 5:S0748-7983(21)00049-4. doi: 10.1016/j.ejso.2021.01.019. Online ahead of print. Impactfactor: 4,424

Baldewpersad Tewarie NM, van Driel WJ, van Ham M, Wouters MW, Kruitwagen R; participants of the Dutch Gynecological Oncology Collaborator Group ([van der Aa MA](#)). Postoperative outcomes of primary and interval cytoreductive surgery for advanced ovarian cancer registered in the Dutch Gynecological Oncology Audit (DGOA). *Gynecol Oncol*. 2021 Aug;162(2):331-338. doi: 10.1016/j.ygyno.2021.05.030. Epub 2021 Jun 17. Impactfactor: 5,482

[Driessen KA](#), [de Rooij BH](#), Vos MC, Boll D, Pijnenborg JM, Hoedjes M, [Beijer S](#), [Ezendam NP](#). Cancer-related psychosocial factors and self-reported changes in lifestyle among gynecological cancer survivors: cross-sectional analysis of PROFILES registry data. *Support Care Cancer*. 2021 Aug 28. doi: 10.1007/s00520-021-06433-0. Online ahead of print. Impactfactor: 3,603

Drost LE, Stegeman M, Mos LM, Lamers RE, [Ezendam NP](#), Gerritse MB, Dam AH, Vos MC. SHARED DEcision making in Pelvic Organ Prolapse (SHADE-POP); Implementation is not as easy as it seems. *Patient Educ Couns*. 2021 Jan 15:S0738-3991(21)00037-9. doi: 10.1016/j.pec.2021.01.010. Online ahead of print. Impactfactor: 2,94

Hermens M, van Altena AM, [van der Aa MA](#), Bulten J, van Vliet HA, Siebers AG, Bekkers RL. Endometrial cancer prognosis in women with endometriosis and adenomyosis. A retrospective nationwide cohort study of 40,840 women. *Int J Cancer*. 2021 Dec 18. doi: 10.1002/ijc.33907. Online ahead of print. Impactfactor: 7,396

Lauby A, Colomban O, Corbaux P, Peron J, [van Wagenveld L](#), Gertych W, Bakrin N, Descargues P, Lopez J, Kepenekian V, Glehen O, Philip CA, Devouassoux-Shisheboran M, Tod M, Freyer G, You B. The increasing prognostic and predictive roles of the tumor primary chemosensitivity assessed by CA-125 elimination rate constant K (KELIM) in ovarian cancer: a narrative review. *Cancers (Basel)*. 2021 Dec 25;14(1):98. doi: 10.3390/cancers14010098. Impactfactor: 6,639

Nagelhout G, Ebisch RM, [van der Hel O](#), Meerkerk GJ, Magnée T, de Bruijn T, van Straaten B. Is smoking an independent risk factor for developing cervical intra-epithelial neoplasia and cervical cancer? A systematic review and meta-analysis. *Expert Rev Anticancer Ther*. 2021 Mar 5:1-14. doi: 10.1080/14737140.2021.1888719. Online ahead of print. Impactfactor: 4,512

[Olthof EP](#), [van der Aa MA](#), Adam JA, Stalpers LJ, [Wenzel HH](#), van der Velden J, Mom CH. The role of lymph nodes in cervical cancer: incidence and identification of lymph node metastases-a literature review. *Int J Clin Oncol*. 2021 Jul 9. doi: 10.1007/s10147-021-01980-2. Online ahead of print. Impactfactor: 3,402

[Said SA](#), [Bretveld RW](#), Koffijberg H, Sonke GS, Kruitwagen RFP, de Hullu JA, van Altena AM, [Siesling S](#), [van der Aa MA](#). Clinicopathologic predictors of early relapse in advanced epithelial ovarian cancer: development of prediction models using nationwide data. *Cancer Epidemiol*. 2021 Sep 8:102008. doi: 10.1016/j.canep.2021.102008. Online ahead of print. Impactfactor: 2,984

Said SA, van der Aa MA, Veldmate G, de Hullu JA, van Altena AM. Oncologic outcomes after splenectomy during initial cytoreductive surgery in advanced epithelial ovarian cancer: a nationwide population-based cohort study. *Acta Obstet Gynecol Scand*. 2021 Nov 1. doi: 10.1111/aogs.14286. Impactfactor: 3,636

Scheepers ER, **de Rooij BH**, Pijnenborg JM, van Huis-Tanja LH, **Ezendam NP**, Hamaker ME. Perceived social support in patients with endometrial or ovarian cancer: a secondary analysis from the ROGY care study. *Gynecol Oncol*. 2021 Jan 13:S0090-8258(20)34246-3. doi: 10.1016/j.ygyno.2020.12.031. Online ahead of print. Impactfactor: 5,482

Schrijver LH, Antoniou AC, Olsson H, Mooij TM, Roos-Blom MJ, Azarang L, Adlard J, Ahmed M, Barrowdale D, Davidson R, Donaldson A, Eeles R, Evans DG, Frost D, Henderson A, Izatt L, Ong KR, Bonadona V, Coupier I, Faivre L, Fricker JP, Gesta P, van Engelen K, Jager A, Menko FH, Mourits MJE, Singer CF, Tan YY, Foretova L, Navratilova M, Schmutzler RK, Ellberg C, Gerdes AM, Caldes T, Simard J, Olah E, Jakubowska A, Rantala J, Osorio A, Hopper JL, Phillips KA, Milne RL, Beth Terry M, Noguès C, Engel C, Kast K, Goldgar DE, van Leeuwen FE, Easton DF, Andrieu N, Rookus MA; Epidemiological Study of Familial Breast Cancer, Gene Etude Prospective Sein Ovaire Sein, Hereditary Breast and Ovarian Cancer Research Group Netherlands (**Siesling S, Verloop J**), and International BRCA1/2 Carrier Cohort Study. Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers: an international cohort study. *Am J Obstet Gynecol*. 2021 Jul;225(1):51.e1-51.e17. doi: 10.1016/j.ajog.2021.01.014. Epub 2021 Jan 22. Impactfactor: 8,661

Skorstad M, **de Rooij BH**, Jeppesen MM, Bergholdt SH, **Ezendam NP**, Bohlin T, Jensen PT, Lindemann K, **van de Poll-Franse LV**, Vistad I. Self-management and adherence to recommended follow-up after gynaecological cancer: results from the international InCHARGE study. *Int J Gynecol Cancer*. 2021 Aug;31(8):1106-1115. doi: 10.1136/ijgc-2020-002377. Epub 2021 Apr 15. Impactfactor: 3,437

Sponholtz SE, **Ezendam NP, de Rooij BH**, Parner E, Mogensen O, Hildebrandt MG, Schledermann D, Markauskas A, Frøding LP, Fuglsang K, Bjørnholt SM, Jensen PT. SENTIREC: the sentinel node mapping in women with cervical cancer study: patient-reported early lymphedema and its impact on quality of life. *Gynecol Oncol*. 2021 Dec 29:S0090-8258(21)01692-9. doi: 10.1016/j.ygyno.2021.12.024. Online ahead of print. Impactfactor: 5,482

van de Vorst RE, Hoogendam JP, **van der Aa MA**, Witteveen PO, Zweemer RP, Gerestein CG. The attributive value of comprehensive surgical staging in clinically early-stage epithelial ovarian carcinoma: a systematic review and meta-analysis. *Gynecol Oncol*. 2021 Apr 10:S0090-8258(21)00317-6. doi: 10.1016/j.ygyno.2021.04.007. Online ahead of print. Impactfactor: 5,482

van Weelden WJ, **Bretveld R**, Romano A, van Erp S, Engels S, Lalisang R, Pijnenborg J, **van der Aa MA**. Trends over time in the incidence and use of hormonal therapy in endometrial cancer: a population-based study in the Netherlands. *Int J Gynecol Cancer*. 2021 May 17:ijgc-2021-002444. doi: 10.1136/ijgc-2021-002444. Online ahead of print. Impactfactor: 3,437

Vistad I, Skorstad M, Demmelmaier I, Småstuen MC, Lindemann K, Wisløff T, **van de Poll-Franse LV**, Berntsen S. Lifestyle and Empowerment Techniques in Survivorship of Gynaecologic Oncology (LETSGO study): a study protocol for a multicentre longitudinal interventional study using mobile health technology and biobanking. *BMJ Open*. 2021 Jul 12;11(7):e050930. doi: 10.1136/bmjopen-2021-050930. Impactfactor: 2,692

Wenzel HH, Bekkers RL, **Lemmens VE, van der Aa MA**, Nijman HW. No improvement in survival of older women with cervical cancer: a nationwide study. *Eur J Cancer*. 2021 May 13;151:159-167. doi: 10.1016/j.ejca.2021.04.014. Online ahead of print. Impactfactor: 9,162

Wenzel HH, Olthof EP, Bekkers RL, Boere IA, Lemmens VE, Nijman HW, Stalpers LJ, van der Aa MA, van der Velden J, Mom CH. Primary or adjuvant chemoradiotherapy for cervical cancer with intraoperative lymph node metastasis: a review. *Cancer Treat Rev.* 2021 Nov 2;102:102311. doi: 10.1016/j.ctrv.2021.102311. Online ahead of print. Impactfactor: 12,111

5.2 Overige publicaties

Laven P, Beltman JJ, Bense JE, van der Aa MA, van Gorp T, Vos MC, Boll D, Arts H, Reesink N, Trimbos JB, Kruitwagen R. Incomplete surgical staging in clinical early-stage ovarian cancer: guidelines versus daily practice. *Surg Open Sci.* 2021 Oct 14;7:6-11. doi: 10.1016/j.sopen.2021.09.002. eCollection 2022 Jan.

6 Hemato-oncologie

6.1 Publicaties met impactfactor

Amaador K, Kersten MJ, **Visser O**, Posthuma EF, Minnema MC, Vos JM, **Dinmohamed AG**. Conditional relative survival in Waldenström's macroglobulinaemia: a population-based study in The Netherlands. *Br J Haematol*. 2021 Nov 4. doi: 10.1111/bjh.17926. Online ahead of print. Impactfactor: 6,998

Amaador K, Kersten MJ, **Visser O**, **Brink M**, Posthuma EF, Minnema MC, Vos JM, **Dinmohamed AG**. Primary therapy and relative survival in patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia: a population-based study in the Netherlands, 1989-2018. *Br J Haematol*. 2021 Oct 3. doi: 10.1111/bjh.17856. Impactfactor: 6,998

Bennink C, van der Klift M, Scheurer H, Sonneveld P, **Duijts SF**. Perspectives on returning to work of multiple myeloma patients: a qualitative interview study. *Eur J Cancer Care (Engl)*. 2021 Jun 21:e13481. doi: 10.1111/ecc.13481. Online ahead of print. Impactfactor: 2,52

Brink M, Groen K, Sonneveld P, Minnema MC, Broijl A, **Dinmohamed AG**, van der Spek E, Levin MD, Ypma PF, de Waal E, Posthuma EF, Zweegman S, van de Donk NW. Decrease in early mortality for newly diagnosed multiple myeloma patients in the Netherlands: a population-based study. *Blood Cancer J*. 2021 Nov 11;11(11):178. doi: 10.1038/s41408-021-00571-8. Impactfactor: 11,037

Brink M, **Visser O**, Zweegman S, Sonneveld P, Broijl A, van de Donk NW, **Dinmohamed AG**. First-line treatment and survival of newly diagnosed primary plasma cell leukemia patients in the Netherlands: a population-based study, 1989-2018. *Blood Cancer J*. 2021 Feb 4;11(2):22. doi: 10.1038/s41408-021-00415-5. Impactfactor: 11,037

Brink M, Kahle XU, Vermaat JS, Zijlstra JM, Chamuleau M, Kersten MJ, **Durmaz M**, Plattel WJ, Lugtenburg PJ, Stevens W, Mous R, de Vries EG, van der Poel MW, Panday PV, Huls G, van Meerten T, Nijland M. Impact of rituximab biosimilars on overall survival in diffuse large B-cell lymphoma: a Dutch population-based study. *Blood Adv*. 2021 Aug 10;5(15):2958-2964. doi: 10.1182/bloodadvances.2021004295. Impactfactor: 6,799

Dinnessen MA, **Visser O**, Tonino SH, Posthuma EF, Blijlevens NM, Kersten MJ, Lugtenburg PJ, **Dinmohamed AG**. Conditional relative survival among patients with follicular lymphoma: a population-based study in the Netherlands. *Blood Cancer J*. 2021 Jan 13;11(1):12. doi: 10.1038/s41408-020-00399-8. Impactfactor: 11,037

Dinnessen MA, **Visser O**, Tonino SH, Posthuma EF, Blijlevens NM, Kersten MJ, Lugtenburg PJ, **Dinmohamed AG**. Risk of second primary malignancies in patients with follicular lymphoma: a population-based study in the Netherlands, 1989-2018. *Blood Cancer J*. 2021 Nov 13;11(11):179. doi: 10.1038/s41408-021-00574-5. Impactfactor: 11,037

Ector GI, **Visser O**, Posthuma EF, Westerweel PE, Janssen JJ, Blijlevens NM, **Dinmohamed AG**. Conditional relative survival among adult patients with chronic myeloid leukemia in the tyrosine kinase inhibitor era: a population-based study in the Netherlands. *Leukemia*. 2021 Feb 18. doi: 10.1038/s41375-021-01174-9. Online ahead of print. Impactfactor: 11,528

Issa D, Seefat RL, **Visser O**, Zweegman S, Lugtenburg PJ, **Dinmohamed AG**, Chamuleau ME. Primary therapy and survival in patients with Burkitt lymphoma in the Netherlands: a population-based study, 1989-2018. *Blood*. 2021 Jan 14;blood.2020009552. doi: 10.1182/blood.2020009552. Online ahead of print. Impactfactor: 23,629

Lindman A, Handberg C, Olesen G, **Duijts SF**. Health-related quality of life and physical functioning in patients participating in a rehabilitation programme, undergoing non-myeloablative allogeneic haematopoietic stem cell transplantation: outcomes from a single arm longitudinal study. *Eur J Cancer Care (Engl)*. 2021 Jul 14. doi: 10.1111/ecc.13478. Online ahead of print. Impactfactor: 2,52

Maas CC, van Klaveren D, Ector GI, Posthuma EF, **Visser O**, Westerweel PE, Janssen JJ, Blijlevens NM, **Dinmohamed AG**. The evolution of the loss of life expectancy in patients with chronic myeloid leukaemia: a population-based study in the Netherlands, 1989-2018. *Br J Haematol*. 2021 Dec 5. doi: 10.1111/bjh.17989. Online ahead of print. Impactfactor: 6,998

Oerlemans S, **Arts LP**, Kieffer JM, Prins J, Hoogendoorn M, van der Poel M, Koster A, Lensen C, Stevens WB, Issa D, Pruijt JF, Oosterveld M, van der Griend R, Nijziel M, Tick L, Posthuma EF, **van de Poll-Franse LV**. Web-Based return of individual patient-reported outcome results among patients with lymphoma: randomized controlled trial. *J Med Internet Res*. 2021 Dec 14;23(12):e27886. doi: 10.2196/27886. Impactfactor: 5,43

Posthuma HL, Zijlstra JM, **Visser O**, Kersten MJ, Lugtenburg PJ, **Dinmohamed AG**. Conditional relative survival among patients with nodular lymphocyte-predominant Hodgkin lymphoma in the Netherlands. *Blood Cancer J*. 2021 May 11;11(5):87. doi: 10.1038/s41408-021-00482-8. Impactfactor: 11,037

Posthuma TS, **Visser O**, te Boekhorst PA, **Dinmohamed AG**. Late excess mortality in essential thrombocythemia: a population-based study in the Netherlands, 2001-2018. *Leukemia*. 2021 Aug 6. doi: 10.1038/s41375-021-01372-5. Impactfactor: 11,528

Schulpen M, Goemans BF, Kaspers GJ, Raaijmakers MH, Zwaan CM, **Karim-Kos HE**. Increased survival disparities among children and adolescents & young adults with acute myeloid leukemia: a Dutch population-based study. *Int J Cancer*. 2021 Dec 16. doi: 10.1002/ijc.33878. Online ahead of print. Impactfactor: 7,396

van der Straten L, Hengeveld PJ, Kater AP, Langerak AW, Levin MD. Treatment approaches to chronic lymphocytic leukemia with high-risk molecular features. *Front Oncol*. 2021 Dec 9;11:780085. doi: 10.3389/fonc.2021.780085. eCollection 2021. Impactfactor: 6,244

Vlooswijk C, **Oerlemans S**, **Ezendam NP**, Schep G, Slot S, Thong MS, **Vissers PA**, **Beijer S**. Physical activity is associated with health related quality of life in lymphoma survivors regardless of body mass index: results from the Profiles registry. *Nutr Cancer*. 2021 Feb 8;1-10. doi: 10.1080/01635581.2021.1881570. Online ahead of print. Impactfactor: 2,9

6.2 Overige publicaties

Slot S, **Dinmohamed AG**, **Visser O**, te Boekhorst PA, Zweegman S. Survival in Primary Myelofibrosis: a population-based analysis in the Netherlands. *Hemasphere*. 2021 Jun 28;5(7):e595. doi: 10.1097/HS9.0000000000000595. eCollection 2021 Jul.

7 Hoofdhalskanker

7.1 Publicaties met impactfactor

Al-Jamaei AA, [van Dijk BA](#), Helder MN, Forouzanfar T, Leemans CR, de Visscher JG. A population-based study of the epidemiology of oral squamous cell carcinoma in the Netherlands 1989-2018, with emphasis on young adults. *Int J Oral Maxillofac Surg*. 2021 Mar 24:S0901-5027(21)00101-6. doi: 10.1016/j.ijom.2021.03.006.

Impactfactor: 2,789

Al-Jamaei AA, Helder MN, Forouzanfar T, Brakenhoff RH, Leemans CR, de Visscher JG, [van Dijk BA](#). Age-group-specific trend analyses of oropharyngeal squamous cell carcinoma incidence from 1989 to 2018 and risk factors profile by age-group in 2015-2018: a population-based study in The Netherlands. *Eur J Cancer Prev*. 2021 Jul 8. doi: 10.1097/CEJ.0000000000000678. Online ahead of print.

Impactfactor: 2,497

Boeve K, Mastik MF, Slagter-Menkema L, [van Dijk BA](#), Roodenburg JL, van der Laan BF, Witjes MJ, van der Vegt B, Schuurin E. Cortactin expression assessment improves patient selection for a watchful waiting strategy in pT1cN0-staged oral squamous cell carcinomas with a tumor infiltration depth below 4 mm. *Head Neck*. 2021 May 19. doi: 10.1002/hed.26746. Online ahead of print.

Impactfactor: 3,147

[Brands MT](#), [Campschroer G](#), [Merckx MA](#), Verbeek AL, [van Dijk BA](#), Geurts SM. Second primary tumours after squamous cell carcinoma of the oral cavity. *Eur J Surg Oncol*. 2021 Apr 20:S0748-7983(21)00387-5. doi: 10.1016/j.ejso.2021.03.242. Online ahead of print.

Impactfactor: 4,424

Forner LE, Dieleman FJ, Shaw RJ, Kanatas A, Butterworth CJ, Kjeller G, Alsner J, Overgaard J, Hillerup S, Hyldegaard O, Arnell P, von Buchwald C, H A M Kaanders J, Smeele LE, Specht L, Johansen J, J H Witjes M, [Merckx MA](#), Jansen EC. Hyperbaric oxygen treatment of mandibular osteoradionecrosis: combined data from the two randomized clinical trials DAHANCA-21 and NWHHT2009-1. *Radiother Oncol*. 2021 Nov 26:S0167-8140(21)09017-4. doi: 10.1016/j.radonc.2021.11.021.

Impactfactor: 6,28

Lebbink CA, van den Broek MF, [Kwast AB](#), Derikx JP, Dierselhuis MP, Kruijff S, Links TP, van Trotsenburg AS, Valk GD, Vriens MR, Verrijn Stuart AA, van Santen HM, [Karim-Kos HE](#). Opposite incidence trends for differentiated and medullary thyroid cancer in young Dutch patients over a 30-Year time span. *Cancers (Basel)*. 2021 Oct 12;13(20):5104. doi: 10.3390/cancers13205104.

Impactfactor: 6,639

Leus AJ, Haisma MS, Terra JB, Diercks GF, Van Kester MS, Halmos GB, Rácz E, [van Dijk BA](#), Plaat BE. Age-related differences in tumour characteristics and prognostic factors for disease progression in cutaneous squamous cell carcinoma of the head and neck. *Acta Derm Venereol*. 2021 Dec 22. doi: 10.2340/actadv.v101.347. Online ahead of print.

Impactfactor: 4,437

Schoonbeek RC, Zwertbroek J, Plaat BE, Takes RP, Ridge JA, Strojjan P, Ferlito A, [van Dijk BA](#), Halmos GB. Determinants of delay and association with outcome in head and neck cancer: a systematic review. *Eur J Surg Oncol*. 2021 Mar 6:S0748-7983(21)00123-2. doi: 10.1016/j.ejso.2021.02.029.

Impactfactor: 4,424

Schoonbeek RC, de Vries J, Bras L, Plaat BE, [van Dijk BA](#), Halmos GB. Determinants of delay in the head and neck oncology care pathway: the next step in value-based health care. *Eur J Cancer Care (Engl)*. 2021 Feb 8:e13419. doi: 10.1111/ecc.13419. Online ahead of print.

Impactfactor: 2,52

Schoonbeek RC, de Jel DV, [van Dijk BA](#), Willems SM, Bloemena E, Hoebbers FJ, van Meerten E, Verbist BM, Smeele LE, Halmos GB, [Merkx MA](#), [Siesling S](#), de Bree R, Takes RP; Dutch Head, Neck Society, the COVID, Cancer-NL consortium. Fewer head and neck cancer diagnoses and faster treatment initiation during COVID-19 in 2020: a nationwide population-based analysis. *Radiother Oncol.* 2021 Dec 13:S0167-8140(21)09049-6. doi: 10.1016/j.radonc.2021.12.005. Online ahead of print. Impactfactor: 6,28

Schoonbeek RC, Bult FF, Plaat BE, Witjes MJ, van der Hoorn A, [van Dijk BA](#), Halmos GB. Incidental findings during the diagnostic work-up in the head and neck cancer pathway: effects on treatment delay and survival. *Oral Oncol.* 2021 May 21;118:105350. doi: 10.1016/j.oraloncology.2021.105350. Online ahead of print. Impactfactor: 5,337

van der Kamp MF, [van Dijk BA](#), Plaat BE, van der Laan BF, Halmos GB. To what extent has the last two decades seen significant progress in the management of older patients with head and neck cancer? *Eur J Surg Oncol.* 2021 Jan 29:S0748-7983(21)00041-X. doi: 10.1016/j.ejso.2021.01.014. Online ahead of print. Impactfactor: 4,424

van Gerwen M, Cooke PV, Alpert N, [Mols F](#), Genden E, Schwartz RM. Patient-reported outcomes following total thyroidectomy and lobectomy in thyroid cancer survivors: an analysis of the PROFILES registry data. *Support Care Cancer.* 2021 Aug 7. doi: 10.1007/s00520-021-06355-x. Impactfactor: 3,603

van Hinte G, Sancak T, Weijts WLJ, [Merkx MA](#), Leijendekkers RA, Nijhuis-van der Sanden MW, Takes R, Speksnijder CM. Effect of elective neck dissection versus sentinel lymph node biopsy on shoulder morbidity and health-related quality of life in patients with oral cavity cancer: a longitudinal comparative cohort study. *Oral Oncol.* 2021 Sep 4;122:105510. doi: 10.1016/j.oraloncology.2021.105510. Online ahead of print. Impactfactor: 5,337

van Hinte G, Leijendekkers RA, [Merkx MA](#), Takes RP, Nijhuis-van der Sanden MW, Speksnijder CM. Identifying unmet needs and limitations in physical health in survivors of Head and Neck Cancer. *Eur J Cancer Care (Engl).* 2021 Mar 11:e13434. doi: 10.1111/ecc.13434. Online ahead of print. Impactfactor: 2,52

Wetzels JG, Meijer GJ, de Haan AF, [Merkx MA](#), Speksnijder CM. Immediate implant placement in edentulous oral cancer patients: a long-term retrospective analysis of 207 patients. *Int J Oral Maxillofac Surg.* 2021 Feb 25:S0901-5027(21)00034-5. doi: 10.1016/j.ijom.2021.01.015. Online ahead of print. Impactfactor: 2,789

7.2 Overige publicaties

Brands MT, Verbeek AL, Geurts SM, [Merkx MA](#). Gepersonaliseerde nacontrole bij patiënten die curatief zijn behandeld voor een plaveiselcelcarcinoom in de mondholte. *Ned Tijdschr Tandheelkd.* 2021 Mar;128(3):167-172. doi: 10.5177/ntvt.2021.03.20112.

8 Huidkanker

8.1 Publicaties met impactfactor

Cook S, Bajwa D, **Hollestein L**, Husain A, Rajan N. A 5-year retrospective review of skin adnexal tumours received at a tertiary dermatopathology service: implications for linked genetic diagnoses. *Br J Dermatol*. 2021 Aug 13. doi: 10.1111/bjd.20701. Online ahead of print. Impactfactor: 9,302

de Haan-Du J, Landman GW, Groenier KH, **Vissers PA, Louwman MW**, Kleefstra N, de Bock GH. The risk of cutaneous squamous cell carcinoma among patients with type 2 diabetes receiving hydrochlorothiazide: a cohort study. *Cancer Epidemiol Biomarkers Prev*. 2021 Sep 6:cebp.0620.2021. doi: 10.1158/1055-9965.EPI-21-0620. Impactfactor: 4,254

Deckers EA, Kruijff S, Bastiaannet E, van Ginkel RJ, **Hoekstra-Weebers JE**, Hoekstra HJ. Obesity is not associated with disease-free interval, melanoma-specific survival, or overall survival in patients with clinical stage IB-II melanoma after SLNB. *J Surg Oncol*. 2021 Jun 4. doi: 10.1002/jso.26555. Online ahead of print. Impactfactor: 3,454

Drucker AM, **Hollestein L**, Na Y, Weinstock MA, Li WQ, Abdel-Qadir H, Chan AW. Association between antihypertensive medications and risk of skin cancer in people older than 65 years: a population-based study. *CMAJ*. 2021 Apr 12;193(15):E508-E516. doi: 10.1503/cmaj.201971. Impactfactor: 8,3

Hollestein LM, Arnspang Pedersen S. Increased cutaneous squamous cell carcinoma risk with hydrochlorothiazide use: is there a safe alternative? *Br J Dermatol*. 2021 Jul 5. doi: 10.1111/bjd.20526. Online ahead of print. Impactfactor: 9,302

Leeneman B, **Schreuder K**, Uyl-de Groot CA, van Akkooi ACJ, Haanen JB, Wakkee M, Franken MG, **Louwman MW**. Stage-specific trends in incidence and survival of cutaneous melanoma in the Netherlands (2003-2018): a nationwide population-based study. *Eur J Cancer*. 2021 Jul 10;154:111-119. doi: 10.1016/j.ejca.2021.06.007. Online ahead of print. Impactfactor: 9,162

Reyn B, van Eycken E, **Louwman M**, Henau K, **Schreuder K**, Brochez L, Garmyn M, Kukutsch NA. Incidence and survival of cutaneous melanoma in Belgium and the Netherlands from 2004-2016: striking differences and similarities of two neighboring countries. *J Eur Acad Dermatol Venereol*. 2021 Mar 3. doi: 10.1111/jdv.17197. Online ahead of print. Impactfactor: 6,166

Reyn B, Van Eycken E, **Louwman MW**, Henau K, **Schreuder K**, Brochez L, Garmyn M, Kukutsch NA. Response to the comment by Suijkerbuijk et al. "Survival of stage IV melanoma in Belgium and the Netherlands". *J Eur Acad Dermatol Venereol*. 2021 Sep 17. doi: 10.1111/jdv.17666. Online ahead of print. Impactfactor: 6,166

Roumen RM, **Schuurman MS, Aarts MJ**, Maaskant-Braat AJ, Vreugdenhil G, **Louwman WJ**. Survival of sentinel node biopsy versus observation in intermediate-thickness melanoma: a Dutch population-based study. *PLoS One*. 2021 May 25;16(5):e0252021. doi: 10.1371/journal.pone.0252021. eCollection 2021. Impactfactor: 3,24

Sacchetto L, Rosso S, Comber H, Bouchardy C, Broganelli P, Galceran J, Hackl M, Katalinic A, **Louwman MW**, Robsahm TE, Tryggvadottir L, Tumino R, Van Eycken E, Walsh PM, Zadnik V, Zanetti R. Skin melanoma deaths within 1 or 3 years from diagnosis in Europe. *Int J Cancer*. 2021 Jan 26. doi: 10.1002/ijc.33479. Online ahead of print. Impactfactor: 7,396

Schreuder K, Hollestein L, Nijsten TE, Wakkee M, Louwman MW. A nationwide study of the incidence and trends of first and multiple basal cell carcinoma in the Netherlands and prediction of future incidence. *Br J Dermatol*. 2021 Nov 2. doi: 10.1111/bjd.20871. Online ahead of print. Impactfactor: 9,302

Tokez S, Wakkee M, Kan W, Venables ZC, Mooyaart AL, Louwman MW, Nijsten T, Hollestein LM. Cumulative incidence and disease-specific survival of metastatic cutaneous squamous cell carcinoma: a nationwide cancer registry study. *J Am Acad Dermatol*. 2021 Oct 12:S0190-9622(21)02644-X. doi: 10.1016/j.jaad.2021.09.067. Impactfactor: 11,527

van Winden ME, Bronkhorst EM, Visch MB, Krekels GA, van der Geer S, Damen GW, Amir A, Aben KK, Gerritsen MJ, van de Kerkhof PC, de Jong EM, Lubeek SF. Predictors of surgical treatment burden, outcomes and overall survival in older adults with basal cell carcinoma: results from the prospective, multicenter BATOA cohort. *J Am Acad Dermatol*. 2021 May 31:S0190-9622(21)01034-3. doi: 10.1016/j.jaad.2021.05.041. Online ahead of print. Impactfactor: 11,527

Venables ZC, Tokez S, Hollestein LM, Mooyaart AL, van den Bos RR, Rous B, Leigh IM, Nijsten T, Wakkee M. Validation of four cutaneous squamous cell carcinoma staging systems using nationwide data. *Br J Dermatol*. 2021 Dec 3. doi: 10.1111/bjd.20909. Online ahead of print. Impactfactor: 9,302

Zhou C, Louwman MW, Wakkee M, van der Veldt A, Grünhagen D, Verhoef C, Mooyaart A, Nijsten T, Hollestein L. Primary melanoma characteristics of metastatic disease: a nationwide cancer registry study. *Cancers (Basel)*. 2021 Sep 2;13(17):4431. doi: 10.3390/cancers13174431. Impactfactor: 6,639

9 Longkanker

9.1 Publicaties met impactfactor

Araghi M, Fidler-Benaoudia M, Arnold M, Rutherford M, Bardot A, Ferlay J, Bucher O, De P, Engholm G, Gavin A, Kozie S, Little A, Møller B, St Jacques N, Tervonen H, Walsh P, Woods R, O'Connell DL, Baldwin D, Elwood M, **Siesling S**, Bray F, Soerjomataram I; ICBP SURVMARK-2 Local Leads; ICBP SURVMARK-2 Academic Reference Group; ICBP Clinical Committee–Lung; ICBP SurvMark-2 Academic Reference Group; ICBP SurvMark-2 academic reference group; ICBP Clinical Committee – Lung; ICBP clinical Committee – lung. *International differences in lung cancer survival by sex, histological type and stage at diagnosis: an ICBP SURVMARK-2 Study*. *Thorax*. 2021 Jul 19;thoraxjnl-2020-216555. doi: 10.1136/thoraxjnl-2020-216555. Online ahead of print. Impactfactor: 9,25

Billings NE, Tromp VN, **van den Hurk CJ**, Becker-Commissaris A, Walraven I. *Health-related quality of life and survival in metastasized non-small cell lung cancer patients with and without a targetable driver mutation*. *Cancers (Basel)*. 2021 Aug 25;13(17):4282. doi: 10.3390/cancers13174282. Impactfactor: 6,639

Billings NE, Tromp VN, Veldhuijzen E, Belderbos J, Aaronson NK, Feldman E, Hoek R, Bogaard HJ, Onwuteaka-Philipsen BD, **van de Poll-Franse LV**, Hugtenburg JG, **van den Hurk CJ**, Becker-Commissaris A, Walraven I. *SYMptom monitoring with Patient-Reported Outcomes using a web application among patients with Lung cancer in the Netherlands (SYMPRO-Lung): study protocol for a stepped-wedge randomised controlled trial*. *BMJ Open*. 2021 Sep 13;11(9):e052494. doi: 10.1136/bmjopen-2021-052494. Impactfactor: 2,692

Damhuis RA, Senan S, Khakwani A, Harden S, Helland Å, Strand TE. *Age-related treatment patterns for stage I NSCLC in three European countries*. *J Geriatr Oncol*. 2021 Nov;12(8):1214-1219. doi: 10.1016/j.jgo.2021.05.005. Impactfactor: 3,599

Evers J, Hendriks LE, de Jaeger K, Wijsman R, de Ruyscher D, Terhaard C, van der Sangen M, **Siesling S**, Struikmans H, **Aarts MJ**. *Corrigendum to "Trends and variations in the treatment of stage I-III small cell lung cancer from 2008 to 2019: a nationwide population-based study from the Netherlands" [Lung Cancer 162C (2021) 61-70]*. *Lung Cancer*. 2021 Dec 29;S0169-5002(21)00640-1. doi: 10.1016/j.lungcan.2021.12.012. Online ahead of print. Impactfactor: 5,705

Evers J, de Jaeger K, Hendriks LE, van der Sangen M, Terhaard C, **Siesling S**, de Ruyscher D, Struikmans H, **Aarts MJ**. *Trends and variations in treatment of stage I-III non-small cell lung cancer from 2008 to 2018: a nationwide population-based study from the Netherlands*. *Lung Cancer*. 2021 Mar 20;155:103-113. doi: 10.1016/j.lungcan.2021.03.013. Impactfactor: 5,705

Evers J, Hendriks LE, De Jaeger K, Wijsman R, de Ruyscher D, Terhaard C, van der Sangen M, **Siesling S**, Struikmans H, **Aarts MJ**. *Trends and variations in the treatment of stage I-III small cell lung cancer from 2008 to 2019: a nationwide population-based study from the Netherlands*. *Lung Cancer*. 2021 Oct 28;162:61-70. doi: 10.1016/j.lungcan.2021.10.011. Online ahead of print. Impactfactor: 5,705

Frissen AR, Burgers S, **van der Zwan JM**, **Raijmakers NJ**, Arber A, **Kunst P**, Aerts J, **Duijts SF**. *Experiences of healthcare professionals with support for mesothelioma patients and their relatives: identified gaps and improvements for care*. *Eur J Cancer Care (Engl)*. 2021 Sep 9:e13509. doi: 10.1111/ecc.13509. Online ahead of print. Impactfactor: 2,52

Ghamati MR, Li WW, van der Heijden EH, Verhagen AF, **Damhuis RA**. Surgery without preoperative histological confirmation of lung cancer: what is the current clinical practice? *J Thorac Dis*. 2021 Oct;13(10):5765-5775. doi: 10.21037/jtd-21-617. Impactfactor: 2,895

Ham L, Geijteman EC, **Aarts MJ**, Kuiper JG, **Kunst PW**, **Raijmakers NJ**, Visser LE, van Zuylen L, Brokaar EJ, **Fransen HP**. Use of potentially inappropriate medication in older patients with lung cancer at the end of life. *J Geriatr Oncol*. 2021 Aug 5:S1879-4068(21)00171-5. doi: 10.1016/j.jgo.2021.07.009. Impactfactor: 3,599

Hendriks LE, Dingemans AC, de Ruyscher DK, **Aarts MJ**, Barberio L, Cornelissen R, Hartemink KJ, van den Heuvel M, Schuurung E, Smit HJ, van der Wekken AJ, Smit EF. Lung Cancer in the Netherlands. *J Thorac Oncol*. 2021 Mar;16(3):355-365. doi: 10.1016/j.jtho.2020.10.012. Impactfactor: 15,609

Koopman B, Cajiao Garcia BN, Kuijpers CC, **Damhuis RA**, van der Wekken AJ, Groen HJ, Schuurung E, Willems SM, van Kempen LC. A nationwide study on the impact of routine testing for *EGFR* mutations in advanced NSCLC reveals distinct survival patterns based on *EGFR* mutation subclasses. *Cancers (Basel)*. 2021 Jul 20;13(14):3641. doi: 10.3390/cancers13143641. Impactfactor: 6,639

Lurvink RJ, Rijken A, Bakkers C, **Aarts MJ**, **Kunst PW**, van de Borne BE, **van Erning FN**, **de Hingh IH**. Synchronous peritoneal metastases from lung cancer: incidence, associated factors, treatment and survival: a Dutch population-based study. *Clin Exp Metastasis*. 2021 Mar 18. doi: 10.1007/s10585-021-10085-z. Online ahead of print. Impactfactor: 5,15

Noordhof AL, **Damhuis RA**, Hendriks LE, de Langen AJ, Timens W, Venmans BJ, van Geffen WH. Prognostic impact of KRAS mutation status for patients with stage IV adenocarcinoma of the lung treated with first-line pembrolizumab monotherapy. *Lung Cancer*. 2021 Apr 5;155:163-169. doi: 10.1016/j.lungcan.2021.04.001. Online ahead of print. Impactfactor: 5,705

Prusak A, **van der Zwan JM**, **Aarts MJ**, Arber A, Cornelissen R, Burgers S, **Duijts SF**. The psychosocial impact of living with mesothelioma: experiences and needs of patients and their carers regarding supportive care. *Eur J Cancer Care (Engl)*. 2021 Aug 2:e13498. doi: 10.1111/ecc.13498. Online ahead of print. Impactfactor: 2,52

Rasing MJ, Peters M, **Aarts MJ**, Herder GJ, van Lindert AS, Schramel FM, van der Meer FS, Verhoeff JJ, van Rossum PS. Adjuvant treatment following irradical resection of stage I-III non-small cell lung cancer: a population-based study. *Curr Probl Cancer*. 2021 Aug 14:100784. doi: 10.1016/j.currprobcancer.2021.100784. Online ahead of print. Impactfactor: 3,187

van Joolingen WH, Rasing MJ, Peters M, van Lindert AS, de Heer LM, **Aarts MJ**, Verhoeff JJ, van Rossum PS. ASO Visual Abstract: Non-small cell lung cancer patients with a high predicted risk of irradical resection-can chemoradiotherapy offer similar survival? *Ann Surg Oncol*. 2021 Nov 20. doi: 10.1245/s10434-021-11061-3. Online ahead of print. Impactfactor: 5,344

van Joolingen WH, Rasing MJ, Peters M, van Lindert AS, de Heer LM, **Aarts MJ**, Verhoeff JJ, van Rossum PS. Non-small-cell lung cancer patients with a high predicted risk of irradical resection: can chemoradiotherapy offer similar survival? *Ann Surg Oncol*. 2021 Oct 30. doi: 10.1245/s10434-021-10982-3. Impactfactor: 5,344

Wind A, **Limbeek R**, **Bretveld H**, van Schijndel R, Smits D, de Jong W, Smit H. Evaluating cancer care networks; a case study of a lung cancer care network. *Int J Health Policy Manag*. 2021 Sep 5. doi: 10.34172/ijhpm.2021.98. Online ahead of print. Impactfactor: 5,007

Winkelman JA, van der Woude L, Heineman DJ, Bahce I, [Damhuis RA](#), Mahtab EAF, Hartemink KJ, Senan S, Maat APWM, Braun J, Paul MA, Dahele M, Dickhoff C. A nationwide population-based cohort study of surgical care for patients with superior sulcus tumors: Results from the Dutch Lung Cancer Audit for Surgery (DLCA-S). *Lung Cancer*. 2021 Sep 7;161:42-48. doi: 10.1016/j.lungcan.2021.08.018. Online ahead of print.
Impactfactor: 5,705

9.2 Overige publicaties

Hopstaken JS, de Ruiter JC, [Damhuis RA](#), de Langen AJ, van Diessen JN, Klomp HM, Klompenhouwer EG, Hartemink KJ. Stage I non-small cell lung cancer: treatment modalities, Dutch daily practice and future perspectives. *Cancer Treat Res Commun*. 2021 May 21;28:100404. doi: 10.1016/j.ctarc.2021.100404. Online ahead of print.

Tomassen ML, [Aarts MJ](#), Peters M, van Lindert A, de Ruyscher DK, Verhoeff JJ, van Rossum PS. Prophylactic cranial irradiation in patients with small cell lung cancer in the Netherlands: a population-based study. *Clin Transl Radiat Oncol*. 2021 Feb 12;27:157-163. doi: 10.1016/j.ctro.2021.02.001. eCollection 2021 Mar.

10 Neuro-oncologie

10.1 Publicaties met impactfactor

Girardi F, Rous B, Stiller CA, Gatta G, Fersht N, Storm HH, Rodrigues JR, Herrmann C, Marcos-Gragera R, Peris-Bonet R, Valkov M, Weir HK, Woods RR, You H, Cueva PA, De P, Di Carlo V, Johannesen TB, Lima CA, Lynch CF, Coleman MP, Allemani C; CONCORD Working Group ([Siesling S](#), [Visser O](#)). The histology of brain tumors for 67 331 children and 671 085 adults diagnosed in 60 countries during 2000-2014: a global, population-based study (CONCORD-3). *Neuro Oncol.* 2021 Oct 1;23(10):1765-1776. doi: 10.1093/neuonc/noab067.
Impactfactor: 12,3

10.2 Overige publicaties

Hoogendijk R, van der Lugt J, van Vuurden D, Kremer LC, Wesseling P, Hoving E, [Karim-Kos HE](#). Survival rates of children and young adolescents with CNS tumors improved in the Netherlands since 1990: a population-based study. *Neuro-Oncology advances* 2021 dec. <https://doi.org/10.1093/oaajnl/vdab183>.

11 Upper GI & HPB

11.1 Publicaties met impactfactor

Al-Kaabi A, van der Post RS, van der Werf LR, Wijnhoven BP, Rosman C, Hulshof MC, van Laarhoven HW, **Verhoeven RH**, Siersema PD. Impact of pathological tumor response after CROSS neoadjuvant chemoradiotherapy followed by surgery on long-term outcome of esophageal cancer: a population-based study. *Acta Oncol*. 2021 Jan 25;1-8. doi: 10.1080/0284186X.2020.1870246. Online ahead of print. Impactfactor: 4,089

Besseling J, Reitsma J, Van Erkelens JA, Schepens MH, Siroen MP, Ziedses des Plantes CM, van Berge Henegouwen MI, Beerepoot LV, Van Voorthuizen T, Van Zuylen L, **Verhoeven RH**, van Laarhoven HW. Use of palliative chemotherapy and ICU admissions in gastric and esophageal cancer patients in the last phase of life: a nationwide observational study. *Cancers (Basel)*. 2021 Jan 5;13(1):E145. doi: 10.3390/cancers13010145. Impactfactor: 6,639

Corten BJ, de Savornin Lohman EA, Leclercq WK, Roumen RM, **Verhoeven RH**, van Zwam PH, de Reuver PR, Dejong CH, Slooter GD. Should all gallbladders be examined routinely or selectively by microscopy after cholecystectomy? population-based Dutch study over a decade. *Br J Surg*. 2021 Jan 31;znaa161. doi: 10.1093/bjs/znaa161. Impactfactor: 6,939

de Jong EJ, Geurts SM, **van der Geest LG**, Besselink MG, Bouwense SA, Buijsen J, de Jong C, Heij LR, Koerkamp BG, de Hingh IH, Hoge C, Kazemier G, van Laarhoven HW, de Meijer VE, Mohammad NH, Strijker M, **Timmermans KC**, Valkenburg-van Iersel LB, Wilmink H, Tjan-Heijnen VC, de Vos-Geelen J; Dutch Pancreatic Cancer Group (DPCG). A population-based study on incidence, treatment, and survival in ampullary cancer in the Netherlands. *Eur J Surg Oncol*. 2021 Mar 6;S0748-7983(21)00119-0. doi: 10.1016/j.ejso.2021.02.028. Online ahead of print. Impactfactor: 4,424

de Jong EJ, Janssen QP, Simons TF, Besselink MG, Bonsing BA, Bouwense SA, Geurts SM, Homs MY, de Meijer VE, Tjan-Heijnen VC, van Laarhoven HW, Valkenburg-van Iersel LB, Wilmink JW, **van der Geest LG**, Groot Koerkamp B, de Vos-Geelen J; Dutch Pancreatic Cancer Group. Real-world evidence of adjuvant gemcitabine plus capecitabine versus gemcitabine monotherapy for pancreatic ductal adenocarcinoma. *Int J Cancer*. 2021 Dec 22. doi: 10.1002/ijc.33916. Online ahead of print. Impactfactor: 7,396

Dijksterhuis WP, Latenstein AE, van Kleef JJ, **Verhoeven RH**, de Vries JH, Slingerland M, Steenhagen E, Heisterkamp J, Timmermans LM, de van der Schueren MA, **van Oijen MG**, **Beijer S**, van Laarhoven HW. Cachexia and dietetic interventions in patients with esophagogastric cancer: a multicenter cohort study. *J Natl Compr Canc Netw*. 2021 Jan 8;1-9. doi: 10.6004/jnccn.2020.7615. Online ahead of print. Impactfactor: 11,908

Dijksterhuis WP, Kalff MC, Wagner AD, **Verhoeven RH**, **Lemmens VE**, **van Oijen MG**, Gisbertz SS, van Berge Henegouwen MI, van Laarhoven HW. Gender differences in treatment allocation and survival of advanced gastroesophageal cancer: a population-based study. *J Natl Cancer Inst*. 2021 Apr 10:djab075. doi: 10.1093/jnci/djab075. Online ahead of print. Impactfactor: 13,506

Huang L, Jansen L, **Verhoeven RH**, Ruurda JP, Van Eycken L, De Schutter H, Johansson J, Lindblad M, Johannesen TB, Zadnik V, Žagar T, Mägi M, Lagarde SM, Bastiaannet E, van de Velde CJH, Schrotz-King P, Brenner H. Largely varying patterns and trends of primary cancer-directed resection for gastric carcinoma with synchronous distant metastasis in Europe and the US: a population-based study calling for further standardization of care. *Ther Adv Med Oncol*. 2021 Jun 28;13:17588359211027837. doi: 10.1177/17588359211027837. eCollection 2021. Impactfactor: 8,168

Kalff MC, Gottlieb-Vedi E, **Verhoeven RH**, van Laarhoven HW, Lagergren J, Gisbertz SS, Markar SR, Henegouwen MI. Presentation, treatment, and prognosis of esophageal carcinoma in a nationwide comparison of Sweden and the Netherlands. *Ann Surg*. 2021 Aug 4. doi: 10.1097/SLA.0000000000005127. Online ahead of print.
Impactfactor: 12,969

Kalff MC, Wagner AD, **Verhoeven RH**, **Lemmens VE**, van Laarhoven HW, Gisbertz SS, van Berge Henegouwen MI; Dutch Upper GI Cancer Audit group. Sex differences in tumor characteristics, treatment, and outcomes of gastric and esophageal cancer surgery: nationwide cohort data from the Dutch Upper GI Cancer Audit. *Gastric Cancer*. 2021 Aug 7. doi: 10.1007/s10120-021-01225-1. Online ahead of print.
Impactfactor: 7,37

Koemans WJ, **Lurvink RJ**, Grootsholten C, **Verhoeven RH**, **de Hingh IH**, van Sandick JW. Synchronous peritoneal metastases of gastric cancer origin: incidence, treatment and survival of a nationwide Dutch cohort. *Gastric Cancer*. 2021 Jan 25. doi: 10.1007/s10120-021-01160-1. Online ahead of print.
Impactfactor: 7,37

Kroese TE, **Dijksterhuis WP**, van Rossum PS, **Verhoeven RH**, Mook S, Mohammad NH, Hulshof MC, van Berge Henegouwen MI, **van Oijen MG**, Ruurda JP, van Laarhoven HW, van Hillegersberg R. Prognosis of interval distant metastases after neoadjuvant chemoradiotherapy for esophageal cancer. *Ann Thorac Surg*. 2021 Feb 18:S0003-4975(21)00306-4. doi: 10.1016/j.athoracsur.2021.01.061. Online ahead of print.
Impactfactor: 4,33

Latenstein AE, Mackay TM, **van der Geest LG**, van Eijck CH, de Meijer VE, Stommel MW, **Vissers PA**, Besselink MG, de Hingh IH; Dutch Pancreatic Cancer Group. Effect of centralization and regionalization of pancreatic surgery on resection rates and survival. *Br J Surg*. 2021 Mar 19;znaa146. doi: 10.1093/bjs/znaa146.
Impactfactor: 6,939

Libânio D, Rodrigues JR, Bento MJ, Ebigbo A, Messmann H, **Verhoeven RH**, van Damme N, Bisschops R, Spaander MC, Dinis-Ribeiro M. Gastric cancer incidence and mortality trends between 2007-2016 in three European countries. *Endoscopy*. 2021 Oct 19. doi: 10.1055/a-1673-1118. Online ahead of print.
Impactfactor: 10,093

Luijten JC, **Vissers PA**, Lingsma H, van Leeuwen N, Rozema T, Siersema PD, Rosman C, van Laarhoven HW, **Lemmens VE**, Nieuwenhuijzen GA, **Verhoeven RH**. Changes in hospital variation in the probability of receiving treatment with curative intent for esophageal and gastric cancer. *Cancer Epidemiol*. 2021 Jan 20;71(Pt A):101897. doi: 10.1016/j.canep.2021.101897. Online ahead of print.
Impactfactor: 2,984

Luijten JC, Nieuwenhuijzen GA, Sosef MN, de Hingh IH, Rosman C, Ruurda JP, van Duijvendijk P, Heisterkamp J, de Steur WO, van Laarhoven HWM, Besselink MG, Groot Koerkamp B, van Santvoort HC, **Lemmens VE**, **Vissers PA**. Impact of nationwide centralization of oesophageal, gastric, and pancreatic surgery on travel distance and experienced burden in the Netherlands. *Eur J Surg Oncol*. 2021 Aug 3:S0748-7983(21)00645-4. doi: 10.1016/j.ejso.2021.07.023. Online ahead of print.
Impactfactor: 4,424

Luijten JC, **Haagsman VC**, Luyer MD, **Vissers PA**, Nederend J, Huysentruyt C, Creemers GJ, Curvers W, van der Sangen M, Heesakkers FB, Schrauwen RW, Jürgens MC, Buster EH, Vincent J, Kneppelhout JK, **Verhoeven RH**, Nieuwenhuijzen GA. Implementation of a regional video multidisciplinary team meeting is associated with an improved prognosis for patients with oesophageal cancer: a mixed methods approach. *Eur J Surg Oncol*. 2021 Apr 21:S0748-7983(21)00448-0. doi: 10.1016/j.ejso.2021.04.020. Online ahead of print.
Impactfactor: 4,424

Mackay TM, [Dijksterhuis WP](#), Latenstein AE, [van der Geest LG](#), Sprangers MA, van Eijck CH, Homs MY, Luelmo SA, Molenaar IQ, van Santvoort H, Schreinemakers JM, Wilmink JW, Besselink MG, van Laarhoven HW, [van Oijen MG](#); Dutch Pancreatic Cancer Group. The impact of cancer treatment on quality of life in patients with pancreatic and periampullary cancer: a propensity score matched analysis. *HPB (Oxford)*. 2021 Sep 25:S1365-182X(21)01623-3. doi: 10.1016/j.hpb.2021.09.003. Impactfactor: 3,647

Pijnappel EN, [Dijksterhuis WP](#), [van der Geest LG](#), de Vos-Geelen J, de Groot JW, Homs MY, Creemers GJ, Mohammad NH, Besselink MG, van Laarhoven HW, Wilmink JW; Dutch Pancreatic Cancer Group. First- and second-line palliative systemic treatment outcomes in a real-world metastatic pancreatic cancer cohort. *J Natl Compr Canc Netw*. 2021 Aug 27:1-8. doi: 10.6004/jnccn.2021.7028. Online ahead of print. Impactfactor: 11,908

Rumgay H, Ferlay J, de Martel C, Georges D, Ibrahim AS, Zheng R, Wei W, [Lemmens VE](#), Soerjomataram I. Global, regional and national burden of primary liver cancer by subtype. *Eur J Cancer*. 2022 Jan;161:108-118. doi: 10.1016/j.ejca.2021.11.023. Epub 2021 Dec 20. Impactfactor: 9,162

Rumgay H, Arnold M, Laversanne M, Whiteman DC, Thrift AP, Wei W, [Lemmens VE](#), Soerjomataram I. International trends in esophageal squamous cell carcinoma and adenocarcinoma incidence. *Am J Gastroenterol*. 2021 May 1;116(5):1072-1076. doi: 10.14309/ajg.0000000000001121. Impactfactor: 10,864

Rijken A, Bakkers C, [van Erning FN](#), [van der Geest LG](#), de Vos-Geelen J, Besselink MG, [Lemmens VE](#), [de Hingh IH](#); Dutch Pancreatic Cancer Group. Incidence, treatment, and survival of synchronous peritoneal metastases in pancreatic cancer: update of a nationwide cohort. *Pancreas*. 2021 Aug 3. doi: 10.1097/MPA.0000000000001857. Online ahead of print. Impactfactor: 3,327

[Rijken A](#), [Lurvink RJ](#), Luyer MD, Nieuwenhuijzen GA, [van Erning FN](#), van Sandick JW, [de Hingh IH](#). The burden of peritoneal metastases from gastric cancer: a systematic review on the incidence, risk factors and survival. *J Clin Med*. 2021 Oct 23;10(21):4882. doi: 10.3390/jcm10214882. Impactfactor: 4,242

Steeghs EM, Gelderblom H, [Ho VK](#), Voorham QJ, Willems SM; PATH consortium, Grünberg K, Ligtenberg MJ. Nationwide evaluation of mutation-tailored treatment of gastrointestinal stromal tumors in daily clinical practice. *Gastric Cancer*. 2021 Apr 28. doi: 10.1007/s10120-021-01190-9. Online ahead of print. Impactfactor: 7,370

Strijker M, van Veldhuisen E, [van der Geest LG](#), Busch OR, Bijlsma MF, Haj Mohammad N, Homs MY, van Hooft JE, Verheij J, de Vos-Geelen J, Wilmink JW, Steyerberg EW, Besselink MG, van Laarhoven HW; Dutch Pancreatic Cancer Group. Readily available biomarkers predict poor survival in metastatic pancreatic cancer. *Biomarkers*. 2021 Mar 5:1-15. doi: 10.1080/1354750X.2021.1893814. Online ahead of print. Impactfactor: 2,658

Stroes CI, Schokker S, Molenaar RJ, Mathôt RA, Bijlsma MF, van der Woude SO, Belo Pereira JP, Hooijer GK, [Verhoeven RH](#), Cats A, Grootsoorten C, van Sandick JW, Creemers GJ, Nieuwenhuijzen GA, Haj Mohammad N, Ruurda JP, Meijer SL, Hulshof MC, van Berge Henegouwen MI, van Laarhoven HW. A Phase II Study Demonstrates No Feasibility of Adjuvant Treatment with Six Cycles of S-1 and Oxaliplatin in Resectable Esophageal Adenocarcinoma, with ERCC1 as Biomarker for Response to SOX. *Cancers (Basel)*. 2021 Feb 17;13(4):839. doi: 10.3390/cancers13040839. Impactfactor: 6,639

van den Boorn HG, Abu-Hanna A, Haj Mohammad N, Hulshof MC, Gisbertz SS, Klarenbeek BR, Slingerland M, Beerepoot LV, Rozema T, Sprangers MA, [Verhoeven RH](#), [van Oijen MG](#), Zwinderman KH, van Laarhoven HW. SOURCE: prediction models for overall survival in patients with metastatic and potentially curable esophageal and gastric cancer. *J Natl Compr Canc Netw*. 2021 Feb 26:1-8. doi:10.6004/jnccn.2020.7631. Online ahead of print. Impactfactor: 11,908

van den Boorn HG, **Dijksterhuis WP, van der Geest LG**, de Vos-Geelen J, Besselink MG, Wilmink JW, **van Oijen MG**, van Laarhoven HW. SOURCE-PANC: a prediction model for patients with metastatic pancreatic ductal adenocarcinoma based on nationwide population-based data. *J Natl Compr Canc Netw*. 2021 Jul 21;jnccn20407. doi: 10.6004/jnccn.2020.7669. Online ahead of print. Impactfactor: 11,908

van den Ende T, de Clercq NC, van Berge Henegouwen MI, Gisbertz SS, Geijssen ED, **Verhoeven RH**, Meijer SL, Schokker S, Dings MPG, Bergman JJGHM, Haj Mohammad N, Ruurda JP, van Hillegersberg R, Mook S, Nieuwdorp M, de Gruijl TD, Soeratrham TT, Ylstra B, van Grieken NC, Bijlsma MF, Hulshof MC, van Laarhoven HW. Neoadjuvant chemoradiotherapy combined with atezolizumab for resectable esophageal adenocarcinoma: a single-arm phase II feasibility trial (PERFECT). *Clin Cancer Res*. 2021 Jun 15;27(12):3351-3359. doi: 10.1158/1078-0432.CCR-20-4443. Epub 2021 Jan 27. Impactfactor: 12,531

van Dongen JC, **van der Geest LG**, de Meijer VE, van Santvoort HC, de Vos-Geelen J, Besselink MG, Groot Koerkamp B, Wilmink JW, van Eijck CH; Dutch Pancreatic Cancer Group. Age and prognosis in patients with pancreatic cancer: a population-based study. *Acta Oncol*. 2021 Dec 22:1-8. doi: 10.1080/0284186X.2021.2016949. Online ahead of print. Impactfactor: 4,089

van Keulen AM, Franssen S, **van der Geest LG**, de Boer MT, Coenraad M, van Driel LM, Erdmann JI, Haj Mohammad N, Heij L, Klümpen HJ, Tjwa E, Valkenburg-van Iersel L, Verheij J, Groot Koerkamp B, Olthof PB; Dutch Hepatocellular, Cholangiocarcinoma Group (DHCG). Nationwide treatment and outcomes of perihilar cholangiocarcinoma. *Liver Int*. 2021 Feb 28. doi: 10.1111/liv.14856. Online ahead of print. Impactfactor: 5,828

van Kleef JJ, **Dijksterhuis WP**, van den Boorn HG, Prins M, **Verhoeven RH**, Gisbertz SS, Slingerland M, Mohammad NH, Creemers GJ, Neelis KJ, Heisterkamp J, Rosman C, Ruurda JP, Kouwenhoven EA, **van de Poll-Franse LV, van Oijen MG**, Sprangers MA, van Laarhoven HW; Dutch Upper GI Cancer Group (DUCG). Prognostic value of patient-reported quality of life for survival in oesophagogastric cancer: analysis from the population-based POCOP study. *Gastric Cancer*. 2021 Jul 12. doi: 10.1007/s10120-021-01209-1. Online ahead of print. Impactfactor: 7,37

van Velzen MJ, **Pape M, Dijksterhuis WP**, Slingerland M, van Voorthuizen T, Beerepoot LV, Creemers GJ, Derks S, Mohammad NH, **Verhoeven RH**, van Laarhoven HW. The association between effectiveness of first-line treatment and second-line treatment in gastro-oesophageal cancer. *Eur J Cancer*. 2021 Aug 20;156:60-69. doi: 10.1016/j.ejca.2021.07.026. Online ahead of print. Impactfactor: 9,162

Voeten DM, Busweiler LA, van der Werf LR, Wijnhoven BP, **Verhoeven RH**, van Sandick JW, van Hillegersberg R, Henegouwen MI; Dutch Upper Gastrointestinal Cancer Audit (DUCA) Group. Outcomes of esophagogastric cancer surgery during eight years of surgical auditing by the Dutch Upper Gastrointestinal Cancer Audit (DUCA). *Ann Surg*. 2021 Jul 29. doi: 10.1097/SLA.0000000000005116. Online ahead of print. Impactfactor: 12,969

Vos EL, Nakauchi M, Gönen M, Castellanos JA, Biondi A, Coit DG, Dikken JL, D'Ugo D, Hartgrink H, Li P, Nishimura M, Schattner M, Song KY, Tang LH, Uyama I, Vardhana S, **Verhoeven RH**, Wijnhoven BP, Strong VE. Risk of lymph node metastasis in T1b gastric cancer: an international comprehensive analysis from the Global Gastric Group (G3) alliance. *Ann Surg*. 2021 Dec 14. doi: 10.1097/SLA.0000000000005332. Online ahead of print. Impactfactor: 12,969

11.2 Proefschriften en promoties

Dijksterhuis WP. Systemic treatment effectiveness in advanced esophagogastric cancer in clinical practice. Amsterdam: Universiteit van Amsterdam; 25 juni 2021. Promotor: HW van Laarhoven. Copromotoren: **MG van Oijen, RH Verhoeven**. Overige leden: MI van Berge Henegouwen, GS Sonke, C van Zuylen, **S Siesling**, MC Hulshof, AD Wagner.

12 Urogenitale kanker

12.1 Publicaties met impactfactor

Badrising SK, Louhanepessy RD, van der Noort V, Kieffer J, Coenen JL, Hamberg P, Beeker A, Wagenaar N, Lam M, Celik F, Loosveld OJ, Oostdijk A, Zuetenhorst H, de Feijter JM, Dezentjé VO, Ras-van Spijk S, Vegt E, Haanen JB, [van de Poll-Franse LV](#), Zwart W, Bergman AM. Integrated analysis of pain, health-related quality of life, and analgesic use in patients with metastatic castration-resistant prostate cancer treated with Radium-223. *Prostate Cancer Prostatic Dis.* 2021 Aug 26. doi: 10.1038/s41391-021-00412-6. Online ahead of print.
Impactfactor: 5,554

Galesloot TE, Grotenhuis AJ, Kolev D, [Aben KK](#), Bryan RT, Catto JW, Cheng KK, Conroy S, Dyrskjøl L, Fleshner NE, James ND, Lamy P, Lindskrog SV, Malats N, Mengual L, Verhaegh G, Zeegers MP, Kiemeny LA, Vermeulen SH. Genome-wide meta-analysis identifies novel genes associated with recurrence and progression in non-muscle-invasive bladder cancer. *Eur Urol Oncol.* 2021 Aug 2:S2588-9311(21)00120-6. doi: 10.1016/j.euo.2021.07.001. Online ahead of print.
Impactfactor: 7,479

[Heesterman BL](#), van der Poel HG, Schoots IG, Mehra N, [Aben KK](#). Prognostic importance of concomitant non-regional lymph node and bone metastases in men with newly diagnosed metastatic prostate cancer. *BJU Int.* 2021 Nov 6. doi: 10.1111/bju.15632.
Impactfactor: 5,588

Hinsenveld FJ, Boormans JL, van der Poel HG, van der Schoot DK, Vis AN, [Aben KK](#), Arends TJ, Ausems PJ, Baselmans D, Berger C, Berrens A, Bickerstaffe H, Bos SD, Braam M, Buddingh KT, Claus S, Dekker K, van Doeveren T, Einerhand S, Fossion L, van Gennep EJ, van Ginkel N, Palacios G, Hermans T, Hobijn MM, van Huystee SH, Jaspers-Valentijn M, Klaver OS, Koldewijn EL, Korsten L, Lenting A, Lentjes KJ, Luiting HB, van der Meer S, Nieuwenhuijzen JA, Noordzij MA, Nooter RI, Notenboom C, Oomen R, van Roermund J, de Rooij J, Roshani H, Schrier BP, van der Slot MA, Somford DM, Stelwagen PJ, Stroux A, van der West A, Wijsman BP, Windt W, van Zanten P, van Beek SC; Dutch Cystectomy Snapshot Group. Intermediate-term survival of robot-assisted versus open radical cystectomy for muscle-invasive and high-risk non-muscle invasive bladder cancer in The Netherlands. *Urol Oncol.* 2021 Jul 21:S1078-1439(21)00277-5. doi: 10.1016/j.urolonc.2021.06.018. Online ahead of print.
Impactfactor: 3,498

Jahreiß MC, Heemsbergen WD, [van Santvoort B](#), Hoogeman M, Dirx M, Pos FJ, Janssen T, Dekker A, Vanneste B, Minken A, Hoekstra C, Smeenk RJ, van Oort IM, Bangma CH, Incrocci L, [Aben KK](#). Impact of advanced radiotherapy on second primary cancer risk in prostate cancer survivors: a nationwide cohort study. *Front Oncol.* 2021 Nov 26;11:771956. doi: 10.3389/fonc.2021.771956. eCollection 2021.
Impactfactor: 6,244

Kuppen MC, Westgeest HM, van den Eertwegh AJ, van Moorselaar RJ, van Oort IM, Tascilar M, Mehra N, Lavalaye J, Somford DM, [Aben KK](#), Bergman AM, de Wit R, van den Bergh AC, de Groot CA, Gerritsen WR. Symptomatic skeletal events and the use of bone health agents in a real-world treated metastatic castration resistant prostate cancer population: results from the CAPRI-study in the Netherlands. *Clin Genitourin Cancer.* 2021 Nov 2:S1558-7673(21)00200-7. doi: 10.1016/j.clgc.2021.10.008. Online ahead of print.
Impactfactor: 2,872

Lamers RE, Cuypers M, de Vries M, [van de Poll-Franse LV](#), Bosch JL, Kil PJ. Differences in treatment choices between prostate cancer patients using a decision aid and patients receiving care as usual: results from a randomized controlled trial. *World J Urol.* 2021 Jul 17. doi: 10.1007/s00345-021-03782-7. Online ahead of print.
Impactfactor: 4,226

Maurits JS, Sedelaar JP, Mulders PF, **Aben KK**, Kiemeney LA, Vrieling A. Skeletal muscle radiodensity and visceral adipose tissue index are associated with survival in renal cell cancer: a multicenter population-based cohort study. *Clin Nutr*. 2021 Nov 19;41(1):131-143. doi: 10.1016/j.clnu.2021.11.012. Online ahead of print.
Impactfactor: 7,324

Richters A, Ripping TM, Kiemeney LA, Leliveld AM, van Rhijn BW, Oddens JR, van Moorselaar RJ, Goossens-Laan CA, Meijer RP, Boormans J; BlaZIB Study Group, Witjes JA, **Aben KK**. Hospital volume is associated with postoperative mortality following radical cystectomy for treatment of bladder cancer. *BJU Int*. 2021 Jan 6. doi: 10.1111/bju.15334. Online ahead of print.
Impactfactor: 5,588

Richters A, Boormans JL, van der Heijden MS, van der Heijden AG, Meijer RP, Mehra N, Kiemeney LA, **Aben KK**. Overall survival of patients receiving cisplatin or carboplatin for primary metastatic urothelial carcinoma of the bladder: a contemporary Dutch nationwide cohort study. *Eur Urol Focus*. 2021 Sep 14:S2405-4569(21)00224-8. doi: 10.1016/j.euf.2021.08.009. Online ahead of print.
Impactfactor: 5,996

Richters A, Meijer RP, Mehra N, Boormans JL, van der Heijden AG, van der Heijden MS, Kiemeney LA, **Aben KK**. Prospective bladder cancer infrastructure for experimental and observational research on bladder cancer: study protocol for the 'trials within cohorts' study ProBCI. *BMJ Open*. 2021 May 18;11(5):e047256. doi: 10.1136/bmjopen-2020-047256.
Impactfactor: 2,692

Tillier CN, Vromans RD, Boekhout AH, Veerman H, Wollersheim BM, van Muilekom HA, Boellaard TN, van Leeuwen PJ, **van de Poll-Franse LV**, van der Poel HG. Individual risk prediction of urinary incontinence after prostatectomy and impact on treatment choice in patients with localized prostate cancer. *Neurourol Urodyn*. 2021 May 18. doi: 10.1002/nau.24703. Online ahead of print.
Impactfactor: 2,696

van Doeveren T, **van der Mark M**, van Leeuwen PJ, Boormans JL, **Aben KK**. Rising incidence rates and unaltered survival for primary upper urinary tract urothelial carcinoma: a Dutch population-based study from 1993 to 2017. *BJU Int*. 2021 Mar 10. doi: 10.1111/bju.15389. Online ahead of print.
Impactfactor: 5,588

van Hoogstraten LM, van Gennep EJ, Kiemeney LA, Witjes JA, Voskuilen CS, Deelen M, Mertens LS, Meijer RP, Boormans JL, Robbrecht DG, Beerepoot LV, **Verhoeven RH**, Ripping TM; BlaZIB Study Group, van Rhijn BW, **Aben KK**, Hermans TJ. Occult lymph node metastases in patients without residual muscle-invasive bladder cancer at radical cystectomy with or without neoadjuvant chemotherapy: a nationwide study of 5417 patients. *World J Urol*. 2021 Sep 28. doi: 10.1007/s00345-021-03839-7. Online ahead of print.
Impactfactor: 4,226

van Ruitenbeek NJ, **Ho VK**, Westgeest HM, Beerepoot LV, Hanssens PE. Validation of the updated renal graded prognostic assessment (GPA) for patients with renal cancer brain metastases treated with gamma knife radiosurgery. *J Neurooncol*. 2021 Jun 25. doi: 10.1007/s11060-021-03793-9. Online ahead of print.
Impactfactor: 4,13

Westgeest HM, Kuppen MC, van den Eertwegh FA, van Oort IM, Coenen JL, van Moorselaar JR, **Aben KK**, Bergman AM, Huinink DT, van den Bosch J, Hendriks MP, Lampe MI, Lavalaye J, Mehra N, Smilde TJ, Somford RD, Tick L, Weijl NI, van de Wouw YA, Gerritsen WR, Groot CA. High-intensity care in the end-of-life phase of castration-resistant prostate cancer patients: results from the Dutch CAPRI-registry. *J Palliat Med*. 2021 Aug 19. doi: 10.1089/jpm.2020.0800. Online ahead of print.
Impactfactor: 2,947

Westgeest HM, Kuppen MC, van den Eertwegh AJ, de Wit R, Bergman AM, van Moorselaar RJ, Coenen JL, van den Bergh AC, Somford DM, Mehra N, van Oort IM, **Aben KK**, Gerritsen WR, Uyl-de Groot CA. The effects of new life-prolonging drugs for metastatic castration-resistant prostate cancer (mCRPC) patients in a real-world population. *Prostate Cancer Prostatic Dis*. 2021 Mar 21. doi: 10.1038/s41391-021-00344-1. Online ahead of print.
Impactfactor: 5,554

Wollersheim BM, **van Eenbergen M**, van Asselt KM, Fossion LM, Koldewijn EL, Oddens JR, Oomens EH, Wijsman BP, **van de Poll-Franse LV**, **Ezendam NP**. Type of treatment, symptoms and patient satisfaction play an important role in primary care contact during prostate cancer follow-up: results from the population-based PROFILES registry. BMC Fam Pract. 2021 Nov 4;22(1):218. doi: 10.1186/s12875-021-01567-w. Impactfactor: 2,497

12.2 Overige publicaties

Heesterman BL, **Olthof EM**, van de Poel HG, van Moorselaar JA., **Aben, KK**. Kwaliteitsregistratie prostaatcarcinoom: ziekenhuisregistratie versus Nederlandse Kankerregistratie. Tijd v Urologie 2021 Feb 11, 34-43.

Ripping TM, Westhoff E, Aaronson NK, Van Hemelrijck M, Rammant E, Witjes JA, Kiemeneij LA, **Aben KK**, Vrieling A. Validation and reliability of the Dutch version of the EORTC QLQ-NMIBC24 Questionnaire Module for patients with non-muscle-invasive bladder cancer. J Patient Rep Outcomes. 2021 Sep 20;5(1):96. doi: 10.1186/s41687-021-00372-4.

van Hoogstraten LM, Witjes JA, **Ripping TM**, Nooter RI, Kiemeneij LA, **Aben KK**; and on behalf of the BlaZIB study Group. Low risk of severe complications after a single, post operative instillation of intravesical chemotherapy in patients with TAG1G2 urothelial bladder carcinoma. Bladder Cancer 7 (2021) 193-203.

(later toegevoegd dus na de analyses, was gemist)

B1 Impactfactoren tijdschriften

Tabel 1 Overzicht tijdschriften met impactfactor

<i>Naam tijdschrift:</i>	<i>Impactfactor:</i>	<i>Aantal publicaties:</i>
Acta Dermato-Venerologica	4,437	1
Acta Oncologica	4,089	2
AJG American Journal of Gastroenterology	10,864	1
AJOG American Journal of Obstetrics and Gynecology	8,661	1
American Journal of Clinical Oncology	2,339	1
Annals of Oncology	32,976	1
Annals of Surgical Oncology	5,344	6
Annals of Surgery	12,969	3
Annals of Thoracic Surgery	4,33	1
AOGS Acta Obstetrica et Gynecologica Scandinavica	3,636	1
Biomarkers	2,658	1
BJC British Journal of Cancer	7,64	1
BJD British Journal of Dermatology	9,302	5
BJH British Journal of Haematology	6,998	3
BJS British Journal of Surgery	6,939	6
BJS Open	3,396	1
BJU International	5,588	3
Blood	23,629	1
Blood Advances	6,799	1
Blood Cancer Journal	11.037	5
BMC Cancer	4,43	1
BMC Family Practice	2,497	2
BMC Palliative Care	3,234	1
BMC Public Health	3,295	1
BMC Women's Health	2,809	1
BMJ Global Health	5,558	1
BMJ Open	2,692	5
Brain and Behavior	2,708	1
Breast Cancer	4,239	1
Breast Cancer Research and Treatment	4,872	6
Cancer	6,86	2
Cancer Epidemiology	2,984	2
Cancer Epidemiology, Biomarkers & Prevention	4,254	2
Cancer treatment reviews	12,111	2
Cancers (Basel)	6,639	14
Clinical & experimental metastasis	5,15	2
Clinical Cancer Research	12,531	1
Clinical Genitourinary Cancer	2,872	1
Clinical Nutrition	7,324	1
Clinical Oncology	4,126	1
CMAJ Canadian Medical Association Journal	8,3	1

Current Oncology	3,677	1
Current Problems in Cancer	3,187	1
Digestive Surgery	2,588	1
Diseases of the Colon & Rectum	4,785	1
EJC European Journal of Cancer	9,162	9
EJSO European Journal of Surgical Oncology	4,424	17
Endocrine Connections	3,335	1
Endoscopy	10,093	1
ESMO Open cancer horizons	6,54	1
European Journal of Cancer Care (Engl.)	2,52	15
European Journal of Cancer Prevention	2,497	1
European Journal of Nutrition	5,619	1
European Journal of Public Health	3,367	1
European Journal of Radiology	3,528	1
European Urology Focus	5,996	1
European Urology Oncology	7,479	1
Expert Review of Anticancer Therapy	4,512	1
Frontiers in Oncology	6,244	2
Frontiers in Public Health	3,709	1
Gastric Cancer	7,37	4
Gynecologic Oncology	5,482	4
Head & Neck	3,147	1
Health and social care in the community	2,821	1
HPB	3,647	1
IJC International Journal of Cancer	7,396	6
International Journal for Quality in Health Care	2,038	1
International Journal of Clinical Oncology	3,402	1
International Journal of Colorectal Disease	2,571	1
International Journal of Gynecological Cancer	3,437	2
International Journal of Health Policy and Management	5,007	1
International Journal of Oral & Maxillofacial Surgery	2,789	2
Internet Interventions	4,333	2
JAAD Journal of the American Academy of Dermatology	11,527	2
JAMA Network Open	8,483	1
JAMA Oncology	31,8	1
JAMA Surgery	14,766	2
JMIR Cancer	0,53	1
JMIR Journal of Medical Internet Research	5,43	1
JNCI Cancer Spectrum	0,58	2
JNCI Journal of the National Cancer Institute	13,506	2
JPSM Journal of Pain and Symptom Management	3,612	2
JTD Journal of Thoracic Disease	2,895	1
Journal of Cancer Survivorship	4,442	6
Journal of Clinical Epidemiology	6,473	1
Journal of Clinical Medicine	4,242	1
Journal of Clinical Pathology	3,411	1
Journal of the European Academy of Dermatology and Ven.	6,166	2
Journal of Geriatric Oncology	3,599	3
Journal of Hematology & Oncology	17,388	1

Journal of Neuro-Oncology	4,13	1
Journal of Palliative Care	2,25	1
Journal of Palliative Medicine	2,947	1
Journal of the national comprehensive cancer network	11,908	4
Journal of Surgical Oncology	3,454	2
Journal of Thoracic Oncology	15,609	1
Leukemia	11,528	2
Liver International	5,828	1
Lung Cancer	5,705	5
Medicine & science in Sports & Exercise	5,411	1
Molecular oncology	6,603	1
Nature Communications	14,919	2
Nature Medicine	53,44	1
Neuro Oncology	12,3	1
Neurourology and Urodynamics	2,696	1
Nutrition and cancer	2,9	1
Oral Oncology	5,337	2
Orphanet Journal of rare diseases	4,123	1
Palliative medicine	4,762	1
Pancreas	3,327	1
Patient Education and Counseling	2,94	2
PharmacoEconomics	4,981	1
Plos One	3,24	1
Preventive Medicine	4,018	1
Prostate cancer and prostatic disease	5,554	2
Psycho-Oncology	3,894	1
Quality of Life Research	4,147	1
Radiotherapy & Oncology	6,28	2
Scientific Reports	4,38	2
Supportive Care in Cancer	3,603	13
Surgical Endoscopy	4,584	1
The Breast	4,38	3
The Lancet Gastroenterology & Hepatology	18,486	1
The Lancet Oncology	41,316	3
Therapeutic advances in gastroenterology	4,409	1
Therapeutic advances in medical oncology	8,168	1
Thorax	9,25	1
Urologic Oncology: Seminars and Original Investigations	3,498	1
World Journal of Urology	4,226	2

Tabel 2 Overzicht tijdschriften zonder impactfactor

<i>Naam tijdschrift:</i>	<i>Aantal publicaties:</i>
AMIA Annual Symposium Proceedings	1
Bladder Cancer	1
BMC Nutrition	1
Cancer Treatment and Research Communications	1

<i>Naam tijdschrift:</i>	<i>Aantal publicaties:</i>
ctRO Clinical and translational radiation oncology	1
HemaSphere	1
JMIR Formative Research	1
Journal of patient-reported outcomes	1
Nederlands Tijdschrift voor Tandheelkunde	1
Neuro-Oncology Advances	1
Sarcoma	1
Surgery Open Science	1
Tijdschrift voor Urologie	1

Integraal Kankercentrum
Nederland
info@iknl.nl
www.iknl.nl

